# CITATION REPORT List of articles citing

Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders

DOI: 10.1093/ecco-jcc/jjx008 Journal of Crohnmand Colitis, 2017, 11, 649-670.

Source: https://exaly.com/paper-pdf/66229672/citation-report.pdf

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1102	Editorial: yoga for QoL in ulcerative colitis-any better than other supportive activities? Authors' reply. <b>2017</b> , 46, 202-203		
1101	Nano-targeting of mucosal addressin cell adhesion molecule-1 identifies bowel inflammation foci in murine model. <b>2017</b> , 12, 1547-1560		7
1100	Faecal Calprotectin and UCEIS Predict Short-term Outcomes in Acute Severe Colitis: Prospective Cohort Study. <i>Journal of Crohn</i> and <i>Colitis</i> , <b>2017</b> , 11, 1309-1316	1.5	24
1099	Occurrence of Anaemia in the First Year of Inflammatory Bowel Disease in a European Population-based Inception Cohort-An ECCO-EpiCom Study. <i>Journal of Crohn</i> and Colitis, <b>2017</b> , 11, 12	1 <del>3</del> -∮22	2 <sup>18</sup>
1098	Laparoscopic Intervention in Acute Crohn's Disease Involving an Ovary. <b>2017</b> , 24, 1040-1045		3
1097	The Young Group of the Italian Society of Colorectal Surgery (You-SICCR). 2017, 21, 251-252		4
1096	Pelvic MRI and CT images are interchangeable for measuring peripouch fat. <b>2017</b> , 7, 12443		6
1095	A multi-centre audit of excess steroid use in 1176 patients with inflammatory bowel disease. <b>2017</b> , 46, 964-973		28
1094	Impact of Histological and Endoscopic Remissions on Clinical Recurrence and Recurrence-free Time in Ulcerative Colitis. <b>2017</b> , 23, 2238-2244		27
1093	Transmembrane TNF-Density, but not Soluble TNF-Level, is Associated with Primary Response to Infliximab in Inflammatory Bowel Disease. <b>2017</b> , 8, e117		17
1092	Is Epstein-Barr virus infection associated with the pathogenesis of microscopic colitis?. <b>2017</b> , 97, 1-3		11
1091	Management of patients with inflammatory bowel disease and spondyloarthritis. 2017, 10, 1363-1374		11
1090	Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. <b>2017</b> , 390, 959-968		157
1089	Surgical management of complicated rectovaginal fistulas and the role of omentoplasty. <b>2017</b> , 21, 945	-952	11
1088	Blood biomarkers reflect integration of severity and extent of endoscopic inflammation in ulcerative colitis. <b>2017</b> , 1, 98-104		9
1087	Alicaforsen in the treatment of pouchitis. <b>2017</b> , 9, 1143-1152		8
1086	Skin Manifestations of Inflammatory Bowel Disease. <b>2017</b> , 53, 413-427		52

1085	A Systematic Review and Meta-Analysis of 6-Thioguanine Nucleotide Levels and Clinical Remission in Inflammatory Bowel Disease. <i>Journal of Crohn</i> and Colitis, <b>2017</b> , 11, 1381-1392	12
1084	Imaging of the small intestine in Crohn's disease: Joint position statement of the Indian Society of Gastroenterology and Indian Radiological and Imaging Association. <b>2017</b> , 36, 487-508	12
1083	Amelioration of Tripterygium wilfordii Polycoride on TNBS/Ethanol-induced Ulcerative Colitis via Inhibiting Lipid Peroxidation and Its Downstream Inflammatory Meditors. <b>2017</b> , 9, 344-352	1
1082	Zeroing in on endoscopic and histologic mucosal healing to reduce the risk of colorectal neoplasia in inflammatory bowel disease. <b>2017</b> , 86, 1012-1014	8
1081	Evidence of the Anti-Inflammatory Effects of Probiotics and Synbiotics in Intestinal Chronic Diseases. <b>2017</b> , 9,	184
1080	Human alpha defensin 5 is a candidate biomarker to delineate inflammatory bowel disease. <b>2017</b> , 12, e0179710	10
1079	Changing Infliximab Prescription Patterns in Inflammatory Bowel Disease: A Population-Based Cohort Study, 1999-2014. <b>2018</b> , 24, 433-439	9
1078	Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis. <b>2018</b> , 63, 1294-1301	44
1077	A safety evaluation of budesonide MMX for the treatment of ulcerative colitis. 2018, 17, 437-444	4
1076	An Update on Surveillance in Ulcerative Colitis. <b>2018</b> , 20, 7	8
1075	What Is the Role of the Inflammatory Bowel Disease Panel in Diagnosis and Treatment?. <b>2018</b> , 16, 618-620	1
1074	Detection of cytomegalovirus by immunohistochemistry of colonic biopsies and quantitative blood polymerase chain reaction: evaluation of agreement in ulcerative colitis. <b>2018</b> , 53, 435-441	5
1073	[Inflammatory bowel disease : What does the clinician want to know from the radiologist?]. <b>2018</b> , 58, 320-325	
1072	The Mexican consensus on the diagnosis and treatment of ulcerative colitis. <b>2018</b> , 83, 144-167	14
1071	Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study. <b>2018</b> , 24, 1099-1105	15
1070	Disagreement Among Gastroenterologists Using the Mayo and Rutgeerts Endoscopic Scores. <b>2018</b> , 24, 254-260	11
1069	Efficacy and Safety of Endoscopic Balloon Dilatation of Ileoanal Pouch Strictures. <b>2018</b> , 24, 1316-1320	12
1068	Cancer and Dysplasia Surveillance. <b>2018</b> , 71-100	

1067	Primary Intestinal Epstein-Barr Virus-associated Natural Killer/T-cell Lymphoproliferative Disorder: A Disease Mimicking Inflammatory Bowel Disease. <i>Journal of Crohn</i> and Colitis, <b>2018</b> , 12, 896-904	1.5	8
1066	Acute severe ulcerative colitis: latest evidence and therapeutic implications. <b>2018</b> , 9, 65-72		32
1065	Combination therapy with cytapheresis plus vedolizumab in a corticosteroid-dependent patient with ulcerative colitis and previous ANTI-TNF-drug failure. <b>2018</b> , 50, 415-417		3
1064	When Do You Start and When Do You Stop Screening for Colon Cancer in Inflammatory Bowel Disease?. <b>2018</b> , 16, 621-623		6
1063	Non-alcoholic fatty liver disease phenotypes in patients with inflammatory bowel disease. <b>2018</b> , 9, 87		39
1062	Fibrosis in ulcerative colitis is directly linked to severity and chronicity of mucosal inflammation. <b>2018</b> , 47, 922-939		55
1061	Reviewing the Risk of Colorectal Cancer in Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis. <b>2018</b> , 24, 269-276		3
1060	The Addition of an Immunosuppressant After Loss of Response to Anti-TNF\(\text{Monotherapy}\) in Inflammatory Bowel Disease: A 2-Year Study. <b>2018</b> , 24, 394-401		9
1059	Expression Patterns of TNF∄MAdCAM1, and STAT3 in Intestinal and Skin Manifestations of Inflammatory Bowel Disease. <i>Journal of Crohn</i> ଢ and Colitis, <b>2018</b> , 12, 347-354	1.5	25
1058	Diffusion-weighted MRI in inflammatory bowel disease. <b>2018</b> , 3, 433-443		13
1058	Diffusion-weighted MRI in inflammatory bowel disease. 2018, 3, 433-443  The Mexican consensus on the diagnosis and treatment of ulcerative colitis. 2018, 83, 144-167		3
1057	The Mexican consensus on the diagnosis and treatment of ulcerative colitis. <b>2018</b> , 83, 144-167  Delayed Ileal Pouch Anal Anastomosis Has a Lower 30-Day Adverse Event Rate: Analysis From the		3
1057	The Mexican consensus on the diagnosis and treatment of ulcerative colitis. 2018, 83, 144-167  Delayed Ileal Pouch Anal Anastomosis Has a Lower 30-Day Adverse Event Rate: Analysis From the National Surgical Quality Improvement Program. 2018, 24, 1833-1839  REDD1/Autophagy Pathway Is Associated with Neutrophil-Driven IL-1[Inflammatory Response in		3
1057 1056 1055	The Mexican consensus on the diagnosis and treatment of ulcerative colitis. 2018, 83, 144-167  Delayed Ileal Pouch Anal Anastomosis Has a Lower 30-Day Adverse Event Rate: Analysis From the National Surgical Quality Improvement Program. 2018, 24, 1833-1839  REDD1/Autophagy Pathway Is Associated with Neutrophil-Driven IL-1[Inflammatory Response in Active Ulcerative Colitis. 2018, 200, 3950-3961  Immunohistochemical Assessment of CD30+ Lymphocytes in the Intestinal Mucosa Facilitates		3 9 52
1057 1056 1055	The Mexican consensus on the diagnosis and treatment of ulcerative colitis. 2018, 83, 144-167  Delayed Ileal Pouch Anal Anastomosis Has a Lower 30-Day Adverse Event Rate: Analysis From the National Surgical Quality Improvement Program. 2018, 24, 1833-1839  REDD1/Autophagy Pathway Is Associated with Neutrophil-Driven IL-1[Inflammatory Response in Active Ulcerative Colitis. 2018, 200, 3950-3961  Immunohistochemical Assessment of CD30+ Lymphocytes in the Intestinal Mucosa Facilitates Diagnosis of Pediatric Ulcerative Colitis. 2018, 63, 1811-1818  How clinicians and pathologists interact concerning inflammatory bowel disease in Italy: An IG-IBD		3 9 52 0
1057 1056 1055 1054	The Mexican consensus on the diagnosis and treatment of ulcerative colitis. 2018, 83, 144-167  Delayed Ileal Pouch Anal Anastomosis Has a Lower 30-Day Adverse Event Rate: Analysis From the National Surgical Quality Improvement Program. 2018, 24, 1833-1839  REDD1/Autophagy Pathway Is Associated with Neutrophil-Driven IL-1[Inflammatory Response in Active Ulcerative Colitis. 2018, 200, 3950-3961  Immunohistochemical Assessment of CD30+ Lymphocytes in the Intestinal Mucosa Facilitates Diagnosis of Pediatric Ulcerative Colitis. 2018, 63, 1811-1818  How clinicians and pathologists interact concerning inflammatory bowel disease in Italy: An IG-IBD survey. 2018, 50, 734-736  Adherence, risk factors of non-adherence and patient's preferred treatment strategy of mesalazine	1.5	3 9 52 0

Putting Evidence into Practice: IBD Surveillance, Chromoendoscopy and Future Directions. <b>2018</b> , 113, 313-316	5
The role of the intestinal microbiota in the pathogenesis and treatment of inflammatory bowel diseases. <b>2018</b> , 29, 21-27	
The adherence to the therapy in inflammatory bowel disease: beyond the number of the tablets. <b>2018</b> , 53, 141-146	11
Quality of care in inflammatory bowel diseases: What is the best way to better outcomes?. <b>2018</b> , $24,2363-2372$	13
1045 Ciclosporin as salvage therapy in steroid-refractory ulcerative colitis: a nurse's guide. <b>2018</b> , 16, 35-	·39
1044 Was der Kliniker vom Radiologen wissen will. <b>2018</b> , 5, 30-37	
Change of treatment modalities over the last 10 years in pediatric patients with inflammatory bowel disease in Switzerland. <b>2018</b> , 30, 1159-1167	6
Associations among body composition, inflammatory profile and disease extent in ulcerative colit patients. <b>2018</b> , 64, 133-139	<b>is</b> 5
Differential Intestinal Mucosa Transcriptomic Biomarkers for Crohn's Disease and Ulcerative Colit <b>2018</b> , 2018, 9208274	is. 16
Short- and long-term efficacy of adalimumab salvage therapy after failure of calcineurin inhibitors in steroid-refractory ulcerative colitis. <b>2018</b> , 53, 1236-1244	1
Hospital Anxiety and Depression Scale (HADS): Validation in Mexican Patients with Inflammatory Bowel Disease. <b>2018</b> , 41, 477-482	13
Clinical significance of soluble immunoglobulins A and G and their coated bacteria in feces of patients with inflammatory bowel disease. <b>2018</b> , 16, 359	23
Clinical characteristics and outcomes of primary sclerosing cholangitis and ulcerative colitis in Japanese patients. <b>2018</b> , 13, e0209352	14
Comparative Effectiveness of Vedolizumab vs. Infliximab Induction Therapy in Ulcerative Colitis: Experience of a Real-World Cohort at a Tertiary Inflammatory Bowel Disease Center. <b>2018</b> , 11, 41-	-45 <sup>14</sup>
The Association of Coloproctology of Great Britain and Ireland consensus guidelines in surgery for inflammatory bowel disease. <b>2018</b> , 20 Suppl 8, 3-117	34
The rectal remnant after total colectomy for colitis - intra-operative,post-operative and longer-term considerations. <b>2018</b> , 53, 1443-1452	3
1033 Real-life chromoendoscopy for dysplasia surveillance in ulcerative colitis. <b>2018</b> , 24, 4069-4076	2
Oral vancomycin induces sustained deep remission in adult patients with ulcerative colitis and primary sclerosing cholangitis. <b>2018</b> , 30, 1247-1252	13

1031	No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials. <b>2018</b> , 113, 1197-1205	Ĵ	31
1030	Primary sclerosing cholangitis leads to dysfunction and loss of MAIT cells. <b>2018</b> , 48, 1997-2004		10
1029	Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life. <b>2018</b> , 48, 1174-1185	2	23
1028	Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis. <b>2018</b> , 31, 572-582		17
1027	Nonbiological therapeutic management of ulcerative colitis. <b>2018</b> , 19, 1747-1757	8	8
1026	Clinicopathological and Molecular Specificities of Inflammatory Bowel Disease-Related Colorectal Neoplastic Lesions: The Role of Inflammation. <i>Journal of Crohn</i> and Colitis, <b>2018</b> , 12, 1486-1498	:	11
1025	Hospital Anxiety and Depression Scale (HADS): Validation in Mexican patients with inflammatory bowel disease. <b>2018</b> , 41, 477-482	1	2
1024	Paradoxical arthritis occurring during anti-TNF in patients with inflammatory bowel disease: histological and immunological features of a complex synovitis. <b>2018</b> , 4, e000667	5	11
1023	Rethinking Colorectal Cancer Screening in IBD, Is It Time to Revisit the Guidelines?. <i>Journal of Crohn</i> and Colitis, <b>2018</b> , 12, 757-759	3	3
1022	Beyond Irritable Bowel Syndrome: The Efficacy of the Low Fodmap Diet for Improving Symptoms in Inflammatory Bowel Diseases and Celiac Disease. <b>2018</b> , 36, 271-280	2	25
1021	DALM, rest in peace: a pathologist's perspective on dysplasia in inflammatory bowel disease in the post-DALM era. <b>2018</b> , 31, 1180-1190	-	19
1020	Food Exclusion Based on IgG Antibodies Alleviates Symptoms in Ulcerative Colitis: A Prospective Study. <b>2018</b> , 24, 1918-1925	-,	7
1019	Updates in colorectal cancer screening in inflammatory bowel disease. <b>2018</b> , 34, 208-216	7	7
1018	Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. <b>2018</b> , 67, 257-291	1	145
1017	Colorectal cancer prevention in patients with ulcerative colitis. <b>2018</b> , 32-33, 103-109	Ĵ	35
1016	Expert opinion for use of faecal calprotectin in diagnosis and monitoring of inflammatory bowel disease in daily clinical practice. <b>2018</b> , 6, 1117-1125	3	33
1015	The treatment of refractory ulcerative colitis. <b>2018</b> , 32-33, 49-57		12
1014	Propolis and Its Potential to Treat Gastrointestinal Disorders. <b>2018</b> , 2018, 2035820		10

1013	De-escalation of Therapy in Inflammatory Bowel Disease. <b>2018</b> , 20, 35	10
1012	Management of HBV reactivation in non-oncological patients. <b>2018</b> , 16, 611-624	7
1011	Severe endoscopic lesions are not associated with more infliximab fecal loss in acute severe ulcerative colitis. <b>2018</b> , 50, 1100-1103	2
1010	A real-world, long-term experience on effectiveness and safety of vedolizumab in adult patients with inflammatory bowel disease: The Cross Pennine study. <b>2018</b> , 50, 1299-1304	29
1009	Vagus Nerve as Modulator of the Brain-Gut Axis in Psychiatric and Inflammatory Disorders. 2018, 9, 44	276
1008	Reviewing the therapeutic role of budesonide in Crohn's disease. <b>2018</b> , 41, 458-471	2
1007	[Evolving Therapeutic Strategies in the Inflammatory Bowel Disease]. <b>2018</b> , 71, 61-68	3
1006	Plasma N-Glycan Signatures Are Associated With Features of 1nflammatory Bowel Diseases. <b>2018</b> , 155, 829-843	47
1005	Outcomes and Management of the Ileal Pouch-Anal Anastomosis in the Elderly. 2018, 16, 275-288	3
1004	Human intestinal pro-inflammatory CD11cCCR2CX3CR1 macrophages, but not their tolerogenic CD11cCCR2CX3CR1 counterparts, are expanded in inflammatory bowel disease. <b>2018</b> , 11, 1114-1126	56
1003	The safety of beclomethasone dipropionate in the treatment of ulcerative colitis. 2018, 17, 963-969	7
1002	Reviewing the therapeutic role of budesonide in Crohn's disease. <b>2018</b> , 41, 458-471	1
1001	Genome-wide DNA Methylation in Treatment-na\( \text{U}\)e Ulcerative Colitis. <i>Journal of Crohn\( \text{L}\) and Colitis</i> , <b>2018</b> , 12, 1338-1347	16
1000	Differential diagnosis of inflammatory bowel disease: imitations and complications. <b>2018</b> , 3, 644-653	44
999	Accuracy of Humanitas Ultrasound Criteria in Assessing Disease Activity and Severity in Ulcerative Colitis: A Prospective Study. <i>Journal of Crohn</i> and Colitis, <b>2018</b> , 12, 1385-1391	40
998	[Comparison of Treatment Guidelines for Ulcerative Colitis: Role of Biologics]. 2018, 71, 192-195	
997	New cross-sectional imaging in IBD. <b>2018</b> , 34, 194-207	13
996	[Inflammatory bowel diseases: Crohn's disease and ulcerative colitis]. <b>2018</b> , 59, 681-693	3

995	Contemporary Medical Management of Acute Severe Ulcerative Colitis. 2019, 25, 56-66	6
994	Expression of neutrophil gelatinase-associated lipocalin (NGAL) in the gut in Crohn's disease. <b>2018</b> , 374, 339-348	18
993	Surgery in ulcerative colitis: When? How?. 2018, 32-33, 71-78	37
992	Clinical disease activity is associated with anxiety and depressive symptoms in adolescents and young adults with inflammatory bowel disease. <b>2018</b> , 48, 358-369	22
991	Significance of serological markers in the disease course of ulcerative colitis in a prospective clinical cohort of patients. <b>2018</b> , 13, e0194166	14
990	Serum anti-glycan-antibodies in relatives of patients with inflammatory bowel disease. <b>2018</b> , 13, e0194222	3
989	Golimumab effectiveness and safety in clinical practice for moderately active ulcerative colitis. <b>2018</b> , 30, 1019-1026	7
988	The impact of biologics in surgical outcomes in ulcerative colitis. <b>2018</b> , 32-33, 79-87	15
987	Predictors of complications and mortality following left colectomy with primary stapled anastomosis for cancer: results of a multicentric study with 1111 patients. <b>2018</b> , 20, 986-995	9
986	Novel score predicts risk for cytomegalovirus infection in ulcerative colitis. <b>2018</b> , 105, 103-108	11
985	Outcomes and prediction of corticosteroid therapy after successive courses of ulcerative colitis treatments. <b>2018</b> , 12, 733-741	4
984	Malignant and Nonmalignant Complications of the Rectal Stump in Patients with Inflammatory Bowel Disease. <b>2019</b> , 25, 377-384	12
983	Faecal calprotectin delivers on convenience, cost reduction and clinical decision-making in inflammatory bowel disease: a real-world cohort study. <b>2019</b> , 49, 94-100	7
982	ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. <i>Journal of Crohn</i> and <i>Colitis</i> , <b>2019</b> , 13, 144-164	427
981	The Risk of Elective Abortion in Women With Crohn's Disease and Ulcerative Colitis: A Nationwide Cohort Study. <b>2019</b> , 25, 561-567	6
980	Management of ulcerative colitis in a real-life setting: An Italian multicenter, prospective, observational AIGO study. <b>2019</b> , 51, 346-351	4
979	Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis. <b>2019</b> , 58, 15-37	46
978	Endoscopy in inflammatory bowel disease: from guidelines to real life. <b>2019</b> , 12, 1756284819865153	12

## (2019-2019)

977	Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease Patients. <b>2019</b> , 55,	7
976	True cytomegalovirus colitis is a poor prognostic indicator in patients with ulcerative colitis flares: the 10-year experience of an academic referral inflammatory bowel disease center. <b>2019</b> , 54, 976-983	14
975	Mucosal gene expression changes induced by anti-TNF treatment in inflammatory bowel disease patients. <b>2019</b> , 80, 831-836	7
974	Effect of Cognitive Behavioral Therapy on Clinical Disease Course in Adolescents and Young Adults With Inflammatory Bowel Disease and Subclinical Anxiety and/or Depression: Results of a Randomized Trial. <b>2019</b> , 25, 1945-1956	8
973	An update on treatment of ulcerative colitis. <b>2019</b> , 7, 295-304	1
972	A multicentre prospective cohort study assessing the effectiveness of budesonide MMX[] (Cortiment[]) for active, mild-to-moderate ulcerative colitis. <b>2019</b> , 7, 1171-1182	5
971	Intra- and Inter-cellular Rewiring of the Human Colon during Ulcerative Colitis. 2019, 178, 714-730.e22	359
970	Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD Study. <b>2020</b> , 26, 450-459	20
969	New markers in ulcerative colitis. <b>2019</b> , 497, 141-146	14
968	Can advanced endoscopic techniques for assessment of mucosal inflammation and healing approximate histology in inflammatory bowel disease?. <b>2019</b> , 12, 1756284819863015	12
967	Conserved transcriptomic profile between mouse and human colitis allows unsupervised patient stratification. <b>2019</b> , 10, 2892	31
966	Efficacy of tofacitinib treatment in ulcerative colitis. <b>2019</b> , 42, 403-412	1
965	Inflammatory Bowel Disease. <b>2019</b> , 373-424	
964	An approach to acute severe ulcerative colitis. <b>2019</b> , 13, 943-955	5
963	Chronic Antibiotic Dependent Pouchitis Is Associated With Older Age at the Time of Ileal Pouch Anal Anastomosis (J-pouch) Surgery. <b>2019</b> , 1, otz029	3
962	Gestion pfiopfatoire des biothfapies en 2019. <b>2019</b> , 5, 274-284	1
961	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 1: Epidemiology, diagnosis and prognosis. <b>2019</b> , 42, 568-578	5
960	Improving the quality of surveillance colonoscopy in inflammatory bowel disease. <b>2019</b> , 4, 971-983	13

959	Long-term follow-up of patients treated with aminosalicylates for ulcerative colitis: Predictive factors of response: An observational case-control study. <b>2019</b> , 7, 1042-1050	2
958	Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease. <b>2019</b> ,	2
957	Reclassifying Pseudopolyps in Inflammatory Bowel Disease: Histologic and Endoscopic Description in the New Era of Mucosal Healing. <b>2019</b> , 1, otz033	2
956	Assessment of steroid use as a key performance indicator in inflammatory bowel disease-analysis of data from 2385 UK patients. <b>2019</b> , 50, 1009-1018	14
955	Endoscopic activity in asymptomatic patients with an ileal pouch is associated with an increased risk of pouchitis. <b>2019</b> , 50, 1189-1194	12
954	Systematic review with network meta-analysis: endoscopic techniques for dysplasia surveillance in inflammatory bowel disease. <b>2019</b> , 50, 858-871	16
953	Maneuvering Clinical Pathways for Ulcerative Colitis. <b>2019</b> , 21, 52	2
952	Biological Treatment and the Potential Risk of Adverse Postoperative Outcome in Patients With Inflammatory Bowel Disease: An Open-Source Expert Panel Review of the Current Literature and Future Perspectives. <b>2019</b> , 1,	3
951	Unmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi Consensus. <b>2019</b> , 2019, 3108025	4
950	Swedish Inflammatory Bowel Disease Register (SWIBREG) - a nationwide quality register. <b>2019</b> , 54, 1089-1101	11
949	Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases. <b>2019</b> , 157, 1032-1043.e1	31
948	Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab. <b>2019</b> , 12, 1756284819869141	2
947	Microbiota modulation-based therapy for luminal GI disorders: current applications of probiotics and fecal microbiota transplantation. <b>2019</b> , 19, 1343-1355	3
946	Effects of preoperative anti-tumour necrosis factor alpha infusion timing on postoperative surgical site infection in inflammatory bowel disease: A systematic review and meta-analysis. <b>2019</b> , 7, 1198-1214	5
945	The intestinal tissue homeostasis - the role of extracellular matrix remodeling in inflammatory bowel disease. <b>2019</b> , 13, 977-993	22
944	Comparison of the efficiency of different enemas on patients with distal ulcerative colitis. <b>2019</b> , 52, e12559	4
943	Morphological, immunohistochemical and molecular features of inflammatory bowel disease associated colorectal carcinoma and associated mucosal lesions - Single institution experience. <b>2019</b> , 215, 730-737	7
942	The Incidence and Definition of Crohn's Disease of the Pouch: A Systematic Review and Meta-analysis. <b>2019</b> , 25, 1474-1480	25

941	Central Venous Sinus Thrombosis in a Boy With Acute Severe Ulcerative Colitis. <b>2019</b> , 7, 19	4
940	Changes in inflammatory bowel disease subtype during follow-up and over time in 44,302 patients. <b>2019</b> , 54, 55-63	22
939	Superiority of Interferon Gamma Assay Over Tuberculin Skin Test for Latent Tuberculosis in Inflammatory Bowel Disease Patients in Brazil. <b>2019</b> , 64, 1916-1922	6
938	Diagnostic delay in patients with inflammatory bowel disease in Austria. <b>2019</b> , 131, 104-112	9
937	Naringenin-loaded nano-structured lipid carrier fortifies oxaliplatin-dependent apoptosis in HT-29 cell line. <b>2019</b> , 83, 168-175	25
936	Even non-experts identify non-dysplastic lesions in inflammatory bowel disease via chromoendoscopy: results of a screening program in real-life. <b>2019</b> , 7, E743-E750	5
935	Clinical value of fecal calprotectin. <b>2019</b> , 56, 307-320	30
934	Impact of anti-TNF-alpha therapy on colectomy rate and indications for colectomy in ulcerative colitis: comparison of two patient cohorts from 2005 to 2007 and from 2014 to 2016. <b>2019</b> , 54, 707-711	7
933	New developments in ulcerative colitis: latest evidence on management, treatment, and maintenance. <b>2019</b> , 8, 212572	54
932	Role of IPAA for Crohn® Disease. <b>2019</b> , 141-149	
93 <sup>2</sup>	Role of IPAA for Crohn Disease. 2019, 141-149  A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis. 2019, 8,	7
	A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to	7
931	A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis. <b>2019</b> , 8,  Illness Perceptions and Depression Are Associated with Health-Related Quality of Life in Youth	
931	A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis. <b>2019</b> , 8,  Illness Perceptions and Depression Are Associated with Health-Related Quality of Life in Youth with Inflammatory Bowel Disease. <b>2019</b> , 26, 415-426	20
931 930 929	A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis. 2019, 8,  Illness Perceptions and Depression Are Associated with Health-Related Quality of Life in Youth with Inflammatory Bowel Disease. 2019, 26, 415-426  Ustekinumab Is Effective for the Treatment of Chronic Antibiotic-Refractory Pouchitis. 2019, 64, 3596-3601  Dose escalation and switching of biologics in ulcerative colitis: a systematic literature review in	20
931 930 929 928	A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis. 2019, 8,  Illness Perceptions and Depression Are Associated with Health-Related Quality of Life in Youth with Inflammatory Bowel Disease. 2019, 26, 415-426  Ustekinumab Is Effective for the Treatment of Chronic Antibiotic-Refractory Pouchitis. 2019, 64, 3596-3601  Dose escalation and switching of biologics in ulcerative colitis: a systematic literature review in real-world evidence. 2019, 35, 1911-1923	20 25 8
931 930 929 928 927	A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis. 2019, 8,  Illness Perceptions and Depression Are Associated with Health-Related Quality of Life in Youth with Inflammatory Bowel Disease. 2019, 26, 415-426  Ustekinumab Is Effective for the Treatment of Chronic Antibiotic-Refractory Pouchitis. 2019, 64, 3596-3601  Dose escalation and switching of biologics in ulcerative colitis: a systematic literature review in real-world evidence. 2019, 35, 1911-1923  Inflammatory bowel disease nurse specialists: sailing into a perfect storm?. 2019, 28, 278-280	20 25 8

923	The Relationship between Serum Bilirubin and Inflammatory Bowel Disease. <b>2019</b> , 2019, 5256460	15
922	A case of screening colonoscopy using linked-color imaging to detect ulcerative colitis-associated colorectal cancer. <b>2019</b> , 51, 1061	1
921	Integrated analysis of circRNAs and mRNAs expression profile revealed the involvement of hsa_circ_0007919 in the pathogenesis of ulcerative colitis. <b>2019</b> , 54, 804-818	14
920	The LIFT procedure for a perianal Crohn's fistula - a video vignette. <b>2019</b> , 21, 853-854	3
919	Clinical and patient reported outcomes of the multidisciplinary management in patients with inflammatory bowel disease-associated spondyloarthritis. <b>2019</b> , 64, 76-84	5
918	Management of elderly ulcerative colitis in Japan. <b>2019</b> , 54, 571-586	12
917	Efficacy and Safety of Adsorptive Granulocyte and Monocyte Apheresis in Elderly and Pregnant Patients With Ulcerative Colitis. <b>2019</b> , 23, 217-223	1
916	Vedolizumab for the treatment of inflammatory bowel diseases: from symptomatic control to mucosal healing. <b>2019</b> , 11, 565-575	2
915	Faecalibacterium prausnitzii produces butyrate to decrease c-Myc-related metabolism and Th17 differentiation by inhibiting histone deacetylase 3. <b>2019</b> , 31, 499-514	28
914	Ulcerative Colitis: Shifting Sands. <b>2019</b> , 19, 227-234	9
913	Updates in the management of inflammatory bowel disease during pregnancy. <b>2019</b> , 210, 276-280	9
912	No Association Between Pseudopolyps and Colorectal Neoplasia in Patients With Inflammatory Bowel Diseases. <b>2019</b> , 156, 1333-1344.e3	36
911	Depression and anxiety have unique contributions to somatic complaints in depression, irritable bowel syndrome and inflammatory bowel diseases. <b>2019</b> , 29, 418-426	2
910	Serum Resolvin E1 Levels and Its Relationship with Disease Activity in Ulcerative Colitis. <b>2019</b> , 2019, 6258327	1
909	Systematic review and meta-analysis of endorectal advancement flap and ligation of the intersphincteric fistula tract for cryptoglandular and Crohn's high perianal fistulas. <b>2019</b> , 3, 231-241	68
908	Contraception, Venous Thromboembolism, and Inflammatory Bowel Disease: What Clinicians (and Patients) Should Know. <b>2019</b> , 25, 1603-1612	9
907	A current overview of corticosteroid use in active ulcerative colitis. <b>2019</b> , 13, 557-561	25
906	Higher education, professional occupation, and upper socioeconomic status are associated with lower adherence to medications in patients with inflammatory bowel disease. <b>2019</b> , 3, 302-309	6

905 Neue medikamentse Anssze bei chronisch-entzsidlichen Darmerkrankungen. **2019**, 41, 5-12

Intestinal CD103+CD4+ and CD103+CD8+ T-Cell Subsets in the Gut of Inflammatory Bowel Disease Patients at Diagnosis and During Follow-up. 2019, 25, 1497-1509  Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab. 2019, 25, 1805-1812  Operative Therapie der Colitis ulcerosa. 2019, 41, 13-21  Operative Therapie der Colitis und Safety of vedolizumab in patients with Inflammatory bowel diseases: A real-life experience from a tertiary referral center. 2019, 20, 235-242  Operative Therapie der Colitis und Safety of Low-Volume Bowel Preparations for Patients with Inflammatory Bowel Diseases: The French Multicentre CLEAN Study. Journal of Crohnis and Colitis, 2019, 13, 1121-1130 <sup>3</sup> 6  Operative Therapie der Colitis und Colitis, 2019, 23, 1067-1080  Operative Therapie der Colitis. 2019, 9, 2358  Operative Therapie der Colitis und Colitis, 2019, 13, 1067-1080  Operative Therapie der Colitis. Journal of Crohnis and Colitis, 2019, 13, 1121-1130 <sup>3</sup> 5  Operative Therapie der Colitis in Two Clinical Trials. Journal of Crohnis and Colitis, 2019, 13, 1121-1130 <sup>3</sup> 5  Operative Therapie der Colitis in Two Clinical Trials. Journal of Crohnis and Colitis, 2019, 13, 11227-1293  Operative Therapie der Colitis in Two Clinical Trials. Journal of Crohnis and Colitis, 2019, 13, 1227-1293  Operative Therapie der Colitis in Two Clinical Trials. Journal of Crohnis and Colitis, 2019, 13, 1227-1293  Operative Therapie Colitis in Two Clinical Trials. Journal of Crohnis and Colitis, 2019, 13, 1227-1293  Operative Therapie Colitis in Two Clinical Trials. Journal of Crohnis and Colitis,			
7902 Operative Therapie der Colitis ulcerosa. 2019, 41, 13-21 7903 Long-term efficacy and safety of vedolizumab in patients with inflammatory bowel diseases: A real-life experience from a tertiary referral center. 2019, 20, 235-242 790 Efficacy, Tolerability, and Safety of Low-Volume Bowel Preparations for Patients with Inflammatory Bowel Diseases: The French Multicentre CLEAN Study. Journal of Crohnils and Colitis, 2019, 13, 1121-1130-5 790 Members of the endocannabinoid system are distinctly regulated in inflammatory bowel disease and colorectal cancer. 2019, 9, 2358 790 Members of the endocannabinoid system are distinctly regulated in inflammatory bowel disease and colorectal cancer. 2019, 9, 2358 791 Decreased Expression of Cystathionine (Synthase Exacerbates Intestinal Barrier Injury in Ulcerative Colitis. Journal of Crohnils and Colitis, 2019, 13, 1067-1080 791 Ulcerative Colitis. Journal of Crohnils and Colitis, 2019, 13, 1067-1080 792 From Patients With Ulcerative Colitis in Two Clinical Trials. Journal of Crohnils and Colitis, 2019, 13, 1227-1233 793 Indirect comparison of vedolizumab and adalimumab for biologic-naive patients with ulcerative colitis. 2019, 54, 178-187 793 Circulating microRNA146b-5p is superior to C-reactive protein as a novel biomarker for monitoring inflammatory bowel disease. 2019, 49, 733-743 794 Inflammatory Bowel Diseases. 2019, 10, 47 795 Weak Cytotoxic T Cells Activation Predicts Low-Grade Dysplasia Persistence in Ulcerative Colitis. 2019, 10, e00061 794 LEUKOCYTAPHERESIS IN THE MANAGEMENT OF SEVERE STEROID-DEPENDENT ULCERATIVE COLITIS. 2019, 58, 529-534 795 From Genetics to Epigenetics, Roles of Epigenetics in Inflammatory Bowel Disease. 2019, 10, 1017 796 Patients' perspectives after switching from infliximab to biosimilar CT-P13 in patients with inflammatory bowel disease: A 12-month prospective cohort study. 2019, 51, 1652-1660 797 Patients' perspectives after switching from infliximab to biosimilar CT-P13 in patients with 1012 perspectives after switching from inflixing p	904		16
real-life experience from a tertiary referral center. 2019, 20, 235-242  good Efficacy, Tolerability, and Safety of Low-Volume Bowel Preparations for Patients with Inflammatory Bowel Diseases: The French Multicentre CLEAN Study. Journal of Crohn's and Colitis, 2019, 13, 1121-1130-5 6  899 Members of the endocannabinoid system are distinctly regulated in inflammatory bowel disease and colorectal cancer. 2019, 9, 2358  898 Decreased Expression of Cystathionine Bynthase Exacerbates Intestinal Barrier Injury in Ulcerative Colitis. Journal of Crohn's and Colitis, 2019, 13, 1067-1080 1.5 13  897 Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical Trials. Journal of Crohn's and Colitis, 2019, 13, 1227-1233 5  896 Indirect comparison of vedolizumab and adalimumab for biologic-naive patients with ulcerative colitis. 2019, 54, 178-187  895 Circulating microRNA146b-5p is superior to C-reactive protein as a novel biomarker for monitoring inflammatory bowel disease. 2019, 49, 733-743  896 Sex Differences in Response to TNF-Inhibiting Drugs in Patients With Spondyloarthropathies or Inflammatory Bowel Diseases. 2019, 10, 47  897 Weak Cytotoxic T Cells Activation Predicts Low-Grade Dysplasia Persistence in Ulcerative Colitis. 2019, 10, e00061 1  898 LEUKOCYTAPHERESIS IN THE MANAGEMENT OF SEVERE STEROID-DEPENDENT ULCERATIVE COLITIS. 2019, 58, 529-534  899 From Genetics to Epigenetics, Roles of Epigenetics in Inflammatory Bowel Disease. 2019, 10, 1017 24  890 From Genetics to Epigenetics, Roles of Epigenetics in Inflammatory Bowel Disease. 2019, 10, 1017 4  889 Patients' perspectives after switching from infliximab to biosimilar CT-P13 in patients with inflammatory bowel disease: A 12-month prospective cohort study. 2019, 51, 1652-1660 4	903		19
Figure 2. The Experience from a tertiary referral center. 2019, 20, 235-242  Figure 2. The French Multicentre CLEAN Study. Journal of Crohnt's and Colitis, 2019, 13, 1121-1130-5  Figure 2. The French Multicentre CLEAN Study. Journal of Crohnt's and Colitis, 2019, 13, 1121-1130-5  Figure 2. The French Multicentre CLEAN Study. Journal of Crohnt's and Colitis, 2019, 13, 1121-1130-5  Figure 2. The French Multicentre CLEAN Study. Journal of Crohnt's and Colitis, 2019, 13, 1121-1130-5  Figure 2. The French Multicentre CLEAN Study. Journal of Crohnt's and Colitis, 2019, 13, 1121-1130-5  Figure 2. The French Multicentre CLEAN Study. Journal of Crohnt's and Colitis, 2019, 13, 1121-1130-5  Figure 2. The French Multicentre Clean Study. Journal of Crohnt's and Colitis, 2019, 13, 1121-1130-5  Figure 2. The French Multicentre Clean Study. Journal of Crohnt's and Colitis, 2019, 13, 1121-1130-5  Figure 2. The French Multicentre Clean Study. Journal of Crohnt's and Colitis, 2019, 13, 1121-1130-5  Figure 2. The French Multicentre Clean Study. Journal of Crohnt's and Colitis, 2019, 13, 1121-1130-5  Figure 2. The French Multicentre Clean Study. Journal of Crohnt's and Colitis, 2019, 13, 1121-1130-5  Figure 2. The French Multicentre Clitis in Two Clinical Trials. Journal of Crohnt's and Colitis, 2019, 13, 1121-1130-5  From Patients With Ulcerative Colitis. Journal of Crohnt's and Colitis, 2019, 13, 1121-1130-5  Figure 2. The French Multicentre Clitis in Two Clinical Trials. Journal of Crohnt's and Colitis, 2019, 13, 1227-1233-5  Figure 2. The French Multicentre Colitis in Two Clinical Trials. Journal of Crohnt's and Colitis, 2019, 13, 1227-1233-5  Figure 2. The French Multicentre Colitis in Two Clinical Trials. Journal of Crohnt's and Colitis, 2019, 13, 1227-1233-5  Figure 2. The French Multicentre Colitis in Two Clinical Trials. Journal of Crohnt's and Colitis, 2019, 13, 1227-1233-5  Figure 2. The French Multicentre Colitis in Two Clinical Trials. Journal of Crohnt's and Colitis in Two Clinical Trials. Journal of Crohnt's and Coli	902	Operative Therapie der Colitis ulcerosa. <b>2019</b> , 41, 13-21	1
Members of the endocannabinoid system are distinctly regulated in inflammatory bowel disease and colorectal cancer. 2019, 9, 2358  898 Decreased Expression of Cystathionine Bynthase Exacerbates Intestinal Barrier Injury in Ulcerative Colitis. Journal of Crohn's and Colitis, 2019, 13, 1067-1080  897 Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical Trials. Journal of Crohn's and Colitis, 2019, 13, 1227-7233  896 Indirect comparison of vedolizumab and adalimumab for biologic-naive patients with ulcerative colitis. 2019, 54, 178-187  897 Sex Differences in Response to TNF-Inhibiting Drugs in Patients With Spondyloarthropathies or Inflammatory Bowel Diseases. 2019, 49, 733-743  898 Weak Cytotoxic T Cells Activation Predicts Low-Grade Dysplasia Persistence in Ulcerative Colitis. 2019, 10, e00061  899 LEUKOCYTAPHERESIS IN THE MANAGEMENT OF SEVERE STEROID-DEPENDENT ULCERATIVE COLITIS. 2019, 58, 529-534  890 From Genetics to Epigenetics, Roles of Epigenetics in Inflammatory Bowel Disease. 2019, 10, 1017  890 Patients' perspectives after switching from infliximab to biosimilar CT-P13 in patients with inflammatory bowel disease: A 12-month prospective cohort study. 2019, 51, 1652-1660  890 Serological investigation of IgG and IgE antibodies against food antigens in patients with	901	· · · · · · · · · · · · · · · · · · ·	8
and colorectal cancer. 2019, 9, 2358  898 Decreased Expression of Cystathionine Bynthase Exacerbates Intestinal Barrier Injury in Ulcerative Colitis. Journal of Crohnis and Colitis, 2019, 13, 1067-1080  897 Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical Trials. Journal of Crohnis and Colitis, 2019, 13, 1227-1233 5  896 Indirect comparison of vedolizumab and adalimumab for biologic-naive patients with ulcerative colitis. 2019, 54, 178-187  897 Sex Differences in Response to TNF-Inhibiting Drugs in Patients With Spondyloarthropathies or Inflammatory Bowel Diseases. 2019, 49, 733-743  898 Sex Differences in Response to TNF-Inhibiting Drugs in Patients With Spondyloarthropathies or Inflammatory Bowel Diseases. 2019, 10, 47  899 Weak Cytotoxic T Cells Activation Predicts Low-Grade Dysplasia Persistence in Ulcerative Colitis. 2019, 10, e00061  892 LEUKOCYTAPHERESIS IN THE MANAGEMENT OF SEVERE STEROID-DEPENDENT ULCERATIVE COLITIS. 2019, 58, 529-534  894 Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation. 2019, 6, e000302  895 From Genetics to Epigenetics, Roles of Epigenetics in Inflammatory Bowel Disease. 2019, 10, 1017  896 20 Patients' perspectives after switching from infliximab to biosimilar CT-P13 in patients with inflammatory bowel disease: A 12-month prospective cohort study. 2019, 51, 1652-1660  898 Serological investigation of IgG and IgE antibodies against food antigens in patients with	900	Efficacy, Tolerability, and Safety of Low-Volume Bowel Preparations for Patients with Inflammatory Bowel Diseases: The French Multicentre CLEAN Study. <i>Journal of Crohn</i> and Colitis, <b>2019</b> , 13, 1121-1130 <sup>1.5</sup>	6
Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical Trials. Journal of Crohnis and Colitis, 2019, 13, 1227-1233 5  Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical Trials. Journal of Crohnis and Colitis, 2019, 13, 1227-1233 5  Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical Trials. Journal of Crohnis and Colitis, 2019, 13, 1227-1233 5  Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis and Colitis, 2019, 13, 1227-1233 5  Rapid Circulating microRNA146b-5p is superior to C-reactive protein as a novel biomarker for monitoring inflammatory bowel disease. 2019, 49, 733-743 25  Sex Differences in Response to TNF-Inhibiting Drugs in Patients With Spondyloarthropathies or Inflammatory Bowel Diseases. 2019, 10, 47  Weak Cytotoxic T Cells Activation Predicts Low-Grade Dysplasia Persistence in Ulcerative Colitis. 2019, 10, e00061 1  Rapid Cytotoxic T Cells Activation Predicts Low-Grade Dysplasia Persistence in Ulcerative Colitis. 2019, 10, e00061 1  Rapid Cytotoxic T Cells Activation Predicts Low-Grade Dysplasia Persistence in Ulcerative Colitis. 2019, 10, e00061 1  Rapid Cytotoxic T Cells Activation Predicts Low-Grade Dysplasia Persistence in Ulcerative Colitis. 2019, 10, e00061 1  Rapid Cytotoxic T Cells Activation Predicts Low-Grade Dysplasia Persistence in Ulcerative Colitis. 2019, 58, 529-534 2  Rapid Circulating microRNA146b-5p is superior to C-reactive protein as a novel biomarker for monitoring inflammatory Bowel Diseases. 2019, 10, 1017 24  Rapid Circulating microRNA146b-5p is superior to C-reactive protein as a novel biomarker for monitoring inflammatory bowel Diseases. 2019, 10, 47  Rapid Circulating microRNA146b-5p is superior to C-reactive protein as a	899		38
From Patients With Ulcerative Colitis in Two Clinical Trials. Journal of Crohnis and Colitis, 2019, 13, 1227-7233 5  Indirect comparison of vedolizumab and adalimumab for biologic-naive patients with ulcerative colitis. 2019, 54, 178-187 3  By Circulating microRNA146b-5p is superior to C-reactive protein as a novel biomarker for monitoring inflammatory bowel disease. 2019, 49, 733-743 25  Sex Differences in Response to TNF-Inhibiting Drugs in Patients With Spondyloarthropathies or Inflammatory Bowel Diseases. 2019, 10, 47 5  Weak Cytotoxic T Cells Activation Predicts Low-Grade Dysplasia Persistence in Ulcerative Colitis. 2019, 10, e00061 1  ELUKOCYTAPHERESIS IN THE MANAGEMENT OF SEVERE STEROID-DEPENDENT ULCERATIVE COLITIS. 2019, 58, 529-534 2  Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation. 2019, 6, e000302 14  Prom Genetics to Epigenetics, Roles of Epigenetics in Inflammatory Bowel Disease. 2019, 10, 1017 24  Patients' perspectives after switching from infliximab to biosimilar CT-P13 in patients with inflammatory bowel disease: A 12-month prospective cohort study. 2019, 51, 1652-1660 4  Serological investigation of IgG and IgE antibodies against food antigens in patients with	898		13
colitis. 2019, 54, 178-187  895 Circulating microRNA146b-5p is superior to C-reactive protein as a novel biomarker for monitoring inflammatory bowel disease. 2019, 49, 733-743  896 Sex Differences in Response to TNF-Inhibiting Drugs in Patients With Spondyloarthropathies or Inflammatory Bowel Diseases. 2019, 10, 47  897 Weak Cytotoxic T Cells Activation Predicts Low-Grade Dysplasia Persistence in Ulcerative Colitis. 2019, 10, e00061  898 LEUKOCYTAPHERESIS IN THE MANAGEMENT OF SEVERE STEROID-DEPENDENT ULCERATIVE COLITIS. 2019, 58, 529-534  899 Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation. 2019, 6, e000302  899 From Genetics to Epigenetics, Roles of Epigenetics in Inflammatory Bowel Disease. 2019, 10, 1017  240 Patients' perspectives after switching from infliximab to biosimilar CT-P13 in patients with inflammatory bowel disease: A 12-month prospective cohort study. 2019, 51, 1652-1660  4 Secological investigation of IgG and IgE antibodies against food antigens in patients with	897	Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical Trials. <i>Journal of Crohn</i> and Colitis, <b>2019</b> , 13, 1227-1233	5
Sex Differences in Response to TNF-Inhibiting Drugs in Patients With Spondyloarthropathies or Inflammatory Bowel Diseases. 2019, 10, 47  Weak Cytotoxic T Cells Activation Predicts Low-Grade Dysplasia Persistence in Ulcerative Colitis. 2019, 10, e00061  LEUKOCYTAPHERESIS IN THE MANAGEMENT OF SEVERE STEROID-DEPENDENT ULCERATIVE COLITIS. 2019, 58, 529-534  Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation. 2019, 6, e000302  14  890 From Genetics to Epigenetics, Roles of Epigenetics in Inflammatory Bowel Disease. 2019, 10, 1017  24  889 Patients' perspectives after switching from infliximab to biosimilar CT-P13 in patients with inflammatory bowel disease: A 12-month prospective cohort study. 2019, 51, 1652-1660  4  Serological investigation of IgG and IgE antibodies against food antigens in patients with	896		3
Inflammatory Bowel Diseases. 2019, 10, 47  Weak Cytotoxic T Cells Activation Predicts Low-Grade Dysplasia Persistence in Ulcerative Colitis. 2019, 10, e00061  LEUKOCYTAPHERESIS IN THE MANAGEMENT OF SEVERE STEROID-DEPENDENT ULCERATIVE COLITIS. 2019, 58, 529-534  Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation. 2019, 6, e000302  14  890 From Genetics to Epigenetics, Roles of Epigenetics in Inflammatory Bowel Disease. 2019, 10, 1017  24  899 Patients' perspectives after switching from infliximab to biosimilar CT-P13 in patients with inflammatory bowel disease: A 12-month prospective cohort study. 2019, 51, 1652-1660  4  Serological investigation of IgG and IgE antibodies against food antigens in patients with	895		25
2019, 10, e00061  LEUKOCYTAPHERESIS IN THE MANAGEMENT OF SEVERE STEROID-DEPENDENT ULCERATIVE COLITIS. 2019, 58, 529-534  Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation. 2019, 6, e000302  14  890 From Genetics to Epigenetics, Roles of Epigenetics in Inflammatory Bowel Disease. 2019, 10, 1017  24  Patients' perspectives after switching from infliximab to biosimilar CT-P13 in patients with inflammatory bowel disease: A 12-month prospective cohort study. 2019, 51, 1652-1660  Serological investigation of IgG and IgE antibodies against food antigens in patients with	894		5
Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation. 2019, 6, e000302  14  890 From Genetics to Epigenetics, Roles of Epigenetics in Inflammatory Bowel Disease. 2019, 10, 1017  24  Patients' perspectives after switching from infliximab to biosimilar CT-P13 in patients with inflammatory bowel disease: A 12-month prospective cohort study. 2019, 51, 1652-1660  Serological investigation of IgG and IgE antibodies against food antigens in patients with	893	, , , , , , , , , , , , , , , , , , ,	1
review, network meta-analysis and economic evaluation. 2019, 6, e000302  From Genetics to Epigenetics, Roles of Epigenetics in Inflammatory Bowel Disease. 2019, 10, 1017  Patients' perspectives after switching from infliximab to biosimilar CT-P13 in patients with inflammatory bowel disease: A 12-month prospective cohort study. 2019, 51, 1652-1660  Serological investigation of IgG and IgE antibodies against food antigens in patients with	892		2
Patients' perspectives after switching from infliximab to biosimilar CT-P13 in patients with inflammatory bowel disease: A 12-month prospective cohort study. <b>2019</b> , 51, 1652-1660  Serological investigation of IgG and IgE antibodies against food antigens in patients with	891		14
inflammatory bowel disease: A 12-month prospective cohort study. <b>2019</b> , 51, 1652-1660  Serological investigation of IgG and IgE antibodies against food antigens in patients with	890	From Genetics to Epigenetics, Roles of Epigenetics in Inflammatory Bowel Disease. <b>2019</b> , 10, 1017	24
	889		4
	888		6

887	Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <b>2019</b> , 114, 733-745	22
886	Mucosal Metabolomic Profiling and Pathway Analysis Reveal the Metabolic Signature of Ulcerative Colitis. <b>2019</b> , 9,	9
885	Recommendations of the Spanish Working Group on Crohn Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 1: Epidemiology, diagnosis and prognosis. <b>2019</b> , 42, 568-578	1
884	Outcome of biological therapies in chronic antibiotic-refractory pouchitis: A retrospective single-centre experience. <b>2019</b> , 7, 1215-1225	11
883	Endoscopic score vs blood cell indices for determining timing of immunomodulator withdrawal in quiescent ulcerative colitis. <b>2019</b> , 9, 17751	4
882	Prevalence of Clostridium difficile infection among hospitalized inflammatory bowel disease patients in Greece. <b>2019</b> , 31, 773-776	2
881	Prevalence and indicators of use of complementary and alternative medicine in Austrian patients with inflammatory bowel disease. <b>2019</b> , 31, 1211-1219	3
880	UEG Week 2019 Poster Presentations. <b>2019</b> , 7, 189-1030	1
879	High-Definition Chromoendoscopy Versus High-Definition White Light Colonoscopy for Neoplasia Surveillance in Ulcerative Colitis: A Randomized Controlled Trial. <b>2019</b> , 114, 1642-1648	22
878	Management of Acute Severe Colitis in the Era of Biologicals and Small Molecules. 2019, 8,	7
877	Is diverting loop ileostomy necessary for completion proctectomy with ileal pouch-anal anastomosis? A multicenter randomized trial of the GETAID Chirurgie group (IDEAL trial): rationale and design (NCT03872271). <b>2019</b> , 19, 192	10
876	Fibrosis Mediators in the Colonic Mucosa of Acute and Healed Ulcerative Colitis. <b>2019</b> , 10, e00082	10
875	Surveillance Colonoscopy for Ulcerative Colitis-Associated Colorectal Cancer Offers Better Overall Survival in Real-World Surgically Resected Cases. <b>2019</b> , 114, 483-489	16
874	Profile of Tofacitinib in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Recent Data. <b>2019</b> , 13, 4091-4105	11
873	Incidence and prevalence of inflammatory bowel disease in Mexico from a nationwide cohort study in a period of 15 years (2000-2017). <b>2019</b> , 98, e16291	23
872	Golimumab in inflammatory bowel diseases: present and future scenarios. <b>2019</b> , 12, 1-9	3
871	Systematic review with meta-analysis: high prevalence and cost of continued aminosalicylate use in patients with ulcerative colitis escalated to immunosuppressive and biological therapies. <b>2019</b> , 49, 364-374	1
870	Diagnostic de colite sur biopsie : dînarche pratique pour les pathologistes. <b>2019</b> , 2019, 38-47	

869	Disease course of inflammatory bowel disease unclassified in a European population-based inception cohort: An Epi-IBD study. <b>2019</b> , 34, 996-1003	11
868	Rates and characteristics of postcolonoscopy colorectal cancer in the Swedish IBD population: what are the differences from a non-IBD population?. <b>2019</b> , 68, 1588-1596	13
867	Withdrawal of Azathioprine in Inflammatory Bowel Disease Patients Who Sustain Remission: New Risk Factors for Relapse. <b>2019</b> , 64, 1612-1621	4
866	Patient's Dietary Beliefs and Behaviours in Inflammatory Bowel Disease. <b>2019</b> , 37, 131-139	44
865	Expression patterns common and unique to ulcerative colitis and celiac disease. <b>2019</b> , 83, 86-94	9
864	Defining Faecal Calprotectin Thresholds as a Surrogate for Endoscopic and Histological Disease Activity in Ulcerative Colitis-a Prospective Analysis. <i>Journal of Crohn</i> and Colitis, <b>2019</b> , 13, 424-430	37
863	'Quality of Care' Standards in Inflammatory Bowel Disease: A Systematic Review. <i>Journal of Crohn</i> and Colitis, <b>2019</b> , 13, 127-137	23
862	Anhedonia in irritable bowel syndrome and in inflammatory bowel diseases and its relationship with abdominal pain. <b>2019</b> , 31, e13531	12
861	Optimal management of acute severe ulcerative colitis. <b>2019</b> , 95, 32-40	9
860	Postoperative Steroid Taper Is Associated With Pelvic Sepsis After Ileal Pouch-anal Anastomosis. <b>2019</b> , 25, 1383-1389	9
859	Prognostic Value of the Burden of Cytomegalovirus Colonic Reactivation Evaluated by Immunohistochemical Staining in Patients with Active Ulcerative Colitis. <i>Journal of Crohn</i> and Colitis, <b>2019</b> , 13, 385-388	9
858	Retention Rate, Persistence and Safety of Adalimumab in Inflammatory Bowel Disease: A Real-Life, 9-Year, Single-Center Experience in Italy. <b>2019</b> , 64, 863-874	5
857	Development and Validation of Risk Matrices Concerning Ulcerative Colitis Outcomes-Bayesian Network Analysis. <i>Journal of Crohn</i> and Colitis, <b>2019</b> , 13, 401-409	7
856	Guideline recommendations for treatment of patients with inflammatory bowel diseases are not implemented in clinical practice-results of a non-representative survey. <b>2019</b> , 34, 431-440	2
855	Illness Perception in Inflammatory Bowel Disease Patients is Different Between Patients With Active Disease or in Remission: A Prospective Cohort Study. <i>Journal of Crohn</i> and <i>Colitis</i> , <b>2019</b> , 13, 417-423	22
854	Safety and efficacy of sucrosomial iron in inflammatory bowel disease patients with iron deficiency anemia. <b>2019</b> , 14, 423-431	13
853	The Accuracy of Adherence Self-report Scales in Patients on Thiopurines for Inflammatory Bowel Disease: A Comparison With Drug Metabolite Levels and Medication Possession Ratios. <b>2019</b> , 25, 919-924	9
852	Vitamin D Deficiency in a Portuguese Cohort of Patients with Inflammatory Bowel Disease: Prevalence and Relation to Disease Activity. <b>2019</b> , 26, 155-162	3

851	Accuracy of diagnostic tests and a new algorithm for diagnosing cytomegalovirus colitis in inflammatory bowel diseases: a diagnostic study. <b>2019</b> , 34, 229-237		9
850	Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis. <i>Journal of Crohn</i> and Colitis, <b>2019</b> , 13, 172-181	1.5	17
849	Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort-An Epi-IBD Study. <i>Journal of Crohn</i> and Colitis, <b>2019</b> , 13, 198-208	1.5	57
848	The Unregulated Probiotic Market. <b>2019</b> , 17, 809-817		133
847	Consecutive negative findings on colonoscopy during surveillance predict a low risk of advanced neoplasia in patients with inflammatory bowel disease with long-standing colitis: results of a 15-year multicentre, multinational cohort study. <b>2019</b> , 68, 615-622		17
846	Defective spleen function in autoimmune gastrointestinal disorders. <b>2020</b> , 15, 225-229		11
845	Endoscopic surveillance strategies for dysplasia in ulcerative colitis. <b>2020</b> , 11, 124-132		3
844	When Family Don't Acknowledge: A Hermeneutic Study of the Experience of Kinship Stigma in Community-Dwelling People With Inflammatory Bowel Disease. <b>2020</b> , 30, 1196-1211		9
843	Risk factors for locally advanced cancer associated with ulcerative colitis: Results of a retrospective multicentric study in the era of biologics. <b>2020</b> , 52, 33-37		2
842	Association Between Indefinite Dysplasia and Advanced Neoplasia in Patients With Inflammatory Bowel Diseases Undergoing Surveillance. <b>2020</b> , 18, 1518-1527.e3		15
841	Development of a Global Rating Scale for Inflammatory Bowel Disease. <b>2020</b> , 3, 4-16		
840	Nationwide validation study of diagnostic algorithms for inflammatory bowel disease in Korean National Health Insurance Service database. <b>2020</b> , 35, 760-768		12
839	Long-Term Bowel Function and Fate of the Ileal Pouch After Restorative Proctocolectomy in Patients With Crohn's Disease: A Systematic Review With Meta-Analysis and Metaregression. <i>Journal of Crohn</i> and Colitis, <b>2020</b> , 14, 418-427	1.5	8
838	Non-conventional mucosal lesions (serrated epithelial change, villous hypermucinous change) are frequent in patients with inflammatory bowel disease-results of molecular and immunohistochemical single institutional study. <b>2020</b> , 476, 231-241		4
837	Portomesenteric Venous Thrombosis in Patients Undergoing Surgery for Medically Refractory Ulcerative Colitis. <b>2020</b> , 26, 283-288		4
836	Anorectal Function After Ileo-Rectal Anastomosis Is Better than Pelvic Pouch in Selected Ulcerative Colitis Patients. <b>2020</b> , 65, 250-259		2
835	Risk of Development of More-advanced Lesions in Patients With Inflammatory Bowel Diseases and Dysplasia. <b>2020</b> , 18, 1528-1536.e5		11
834	Are we choosing wisely for inflammatory bowel disease care? The IG-IBD choosing wisely campaign. <b>2020</b> , 52, 44-50		7

833	Clinical significance of isolated abnormal intestinal findings in magnetic resonance enterography in patients with suspected small bowel disease. <b>2020</b> , 45, 1036-1043	
832	Identification of Target Golimumab Levels in Maintenance Therapy of Crohn's Disease and Ulcerative Colitis Associated With Mucosal Healing. <b>2020</b> , 26, 766-773	3
831	Real-Life Effectiveness and Safety of Golimumab and Its Predictors of Response in Patients with Ulcerative Colitis. <b>2020</b> , 65, 1767-1776	5
830	Performance measures in inflammatory bowel disease surveillance colonoscopy: Implementing changes to practice improves performance. <b>2020</b> , 32, 592-599	1
829	Monitoring of infliximab trough levels and anti-infliximab antibodies in inflammatory bowel diseases: A comparison of three commercially available ELISA kits. <b>2020</b> , 126, 154859	10
828	Heat-shock transcription factor 2 promotes sodium butyrate-induced autophagy by inhibiting mTOR in ulcerative colitis. <b>2020</b> , 388, 111820	8
827	Clinical assessment of risk factors for infection in inflammatory bowel disease patients. <b>2020</b> , 35, 491-500	5
826	Mucosal gene transcription of ulcerative colitis in endoscopic remission. <b>2020</b> , 55, 139-147	4
825	Stigmatisation and resilience in inflammatory bowel disease. <b>2020</b> , 15, 211-223	11
824	Spacing the Administration Interval of Anti-TNF Agents: A Valid Strategy for Patients with Inflammatory Bowel Disease?. <b>2020</b> , 65, 2036-2043	2
823	Controversies and Future of Minimally Invasive Surgery for Inflammatory Bowel Disease. <b>2020</b> , 98, 503-506	
822	Effects of anti-TNF-alpha therapy on hemoglobin levels and anemia in patients with inflammatory bowel disease. <b>2020</b> , 52, 400-407	6
821	Efficacy of JAK inhibitors in Ulcerative Colitis. <i>Journal of Crohn</i> and Colitis, <b>2020</b> , 14, S737-S745 1.5	5
820	Inflammatory bowel disease versus Chlamydia trachomatis infection: a case report and revision of the literature. <b>2020</b> , 32, 454-457	1
819	Different Intraepithelial CD3+ Cell Numbers in Crohn's Disease and Ulcerative Colitis. <b>2020</b> , 26, e14-e15	1
818	Endoscopic alterations in Peyer's patches in patients with ulcerative colitis: A prospective, multicenter study. <b>2020</b> , 35, 1143-1149	2
817	Point-of-Care Ultrasound to Diagnose Colitis in the Emergency Department: A Case Series and Review of the Literature. <b>2019</b> ,	1
816	Combining faecal calprotectin and sigmoidoscopy can predict mucosal healing in paediatric ulcerative colitis. <b>2020</b> , 32, 17-21	1

815	Cytomegalovirus in Steroid-Refractory Immune Checkpoint Inhibition-Related Colitis. <b>2020</b> , 15, e15-e20	2
814	Somatic inflammatory gene mutations in human ulcerative colitis epithelium. <b>2020</b> , 577, 254-259	87
813	Long-term deep remission during maintenance therapy with biological agents in inflammatory bowel diseases. <b>2020</b> , 55, 34-40	5
812	How to manage IBD in the 'elderly'. <b>2020</b> , 11, 468-477	5
811	Use of Cross-Sectional Imaging for Tight Monitoring of Inflammatory Bowel Diseases. <b>2020</b> , 18, 1309-1323.e4	17
810	Cost-effectiveness analysis of infliximab, adalimumab, golimumab, vedolizumab and tofacitinib for moderate to severe ulcerative colitis in Spain. <b>2020</b> , 27, 355-360	2
809	Betting on quality indicators to improve inflammatory bowel disease surveillance outcome: All-in or one to pick?. <b>2020</b> , 32, 523-525	О
808	A review of endoscopic scoring systems and their importance in a treat-to-target approach in inflammatory bowel disease (with videos). <b>2020</b> , 91, 733-745	13
807	The endoscopic diagnosis of mucosal healing and deep remission in inflammatory bowel disease. <b>2021</b> , 33, 1008-1023	3
806	Discovery and validation of mucosal TNF expression combined with histological score - a biomarker for personalized treatment in ulcerative colitis. <b>2020</b> , 20, 321	2
805	Efficacy of iron supplementation in patients with inflammatory bowel disease treated with anti-tumor necrosis factor-alpha agents. <b>2020</b> , 13, 1756284820961302	2
804	High-Fat Diet Promotes DSS-Induced Ulcerative Colitis by Downregulated FXR Expression through the TGFB Pathway. <b>2020</b> , 2020, 3516128	5
803	Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients. <b>2020</b> , 10, 17774	3
802	Mesalamine in the Initial Therapy of Ulcerative Colitis. <b>2020</b> , 49, 689-704	2
801	Assessing Severity of Disease in Patients with Ulcerative Colitis. 2020, 49, 671-688	10
800	Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis. <b>2020</b> ,	10
799	Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy. <b>2021</b> , 19, 2567-2576.e9	2
798	IBD considerations in spondyloarthritis. <b>2020</b> , 12, 1759720X20939410	6

797	Experiences of using vedolizumab in the treatment of inflammatory bowel disease in the East Midlands UK - a retrospective observational study. <b>2020</b> , 55, 907-916	2
796	A 3-year prospective study of a multidisciplinary early proactive therapeutic drug monitoring programme of infliximab treatments in inflammatory bowel disease. <b>2020</b> , 86, 1165-1175	11
795	Surgery for Crohn's disease during pregnancy: a difficult decision. <b>2020</b> , 8, 633-634	O
794	Dysplasia in the mucosal biopsy specimen is still a warning sign of cancer in ulcerative colitis. <b>2020</b> , 55, 1019-1023	
793	Tofacitinib in Treatment-Refractory Moderate to Severe Ulcerative Colitis: Real-World Experience from a Retrospective Multicenter Observational Study. <b>2020</b> , 9,	10
792	Risk of Postoperative Infectious Complications From Medical Therapies in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. <b>2020</b> , 26, 1796-1807	5
791	Chromoendoscopy With Indigo Carmine vs Virtual Chromoendoscopy (iSCAN 1) for Neoplasia Screening in Patients With Inflammatory Bowel Disease: A Prospective Randomized Study. <b>2021</b> , 27, 1256-1262	3
790	Concomitant 5-Aminosalicylate Therapy in Moderate-to-Severe Ulcerative Colitis Patients Escalated to Infliximab Is Not Beneficial. <b>2021</b> , 66, 3985-3992	O
789	Adjuvant use of combination of antibiotics in acute severe ulcerative colitis: A placebo controlled randomized trial. <b>2021</b> , 19, 949-955	7
788	Risk of a post-colonoscopy colorectal cancer diagnosis in patients with inflammatory bowel disease: a population-based cohort study. <b>2021</b> , 53, 1023-1033	3
787	A Machine Learning Model Accurately Predicts Ulcerative Colitis Activity at One Year in Patients Treated with Anti-Tumour Necrosis Factor Agents. <b>2020</b> , 56,	5
786	HIGH PREVALENCE OF UNTREATED AND UNDERTREATED VITAMIN D DEFICIENCY AND INSUFFICIENCY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. <b>2020</b> , 59, 109-118	2
785	Impact of obesity on disease activity and disease outcome in inflammatory bowel disease: Results from the Swiss inflammatory bowel disease cohort. <b>2020</b> , 8, 1196-1207	7
784	Enfermedades del recto. <b>2020</b> , 13, 441-447	
783	Molecular Changes in the Non-Inflamed Terminal Ileum of Patients with Ulcerative Colitis. 2020, 9,	2
782	Leucine-rich alpha-2 glycoprotein 1, high mobility group box 1, matrix metalloproteinase 3 and annexin A1 as biomarkers of ulcerative colitis endoscopic and histological activity. <b>2020</b> , 32, 1106-1115	5
781	Restorative surgery for ulcerative colitis in the elderly: an analysis of ileal pouch-anal anastomosis procedures from the American College of Surgeons National Surgical Quality Improvement Program. <b>2020</b> , 24, 1255-1262	1
780	Endoscopic and histologic activity assessment considering disease extent and prediction of treatment failure in ulcerative colitis. <b>2020</b> , 55, 1157-1162	2

779	Treat to target or 'treat to clear' in inflammatory bowel diseases: one step further?. <b>2020</b> , 14, 807-817		5
778	Risk factors for ulcerative colitis-associated colorectal cancer: A retrospective cohort study. <b>2020</b> , 99, e21686		3
777	The amelioration of ulcerative colitis induced by Dinitrobenzenesulfonic acid with Radix Hedysari. <b>2020</b> , 44, e13421		1
776	Cytomegalovirus and Inflammatory Bowel Diseases (IBD) with a Special Focus on the Link with Ulcerative Colitis (UC). <b>2020</b> , 8,		9
775	The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surgical Management of Crohn's Disease. <b>2020</b> , 63, 1028-1052		11
774	Review of normal gastrointestinal tract, ulcerative colitis, proctitis and rectal medication adherence. <b>2020</b> , 29, 805-811		1
773	Long-Term Follow-Up of Targeted Biopsy Yield (LOFTY Study) in Ulcerative Colitis Surveillance Colonoscopy. <b>2020</b> , 9,		2
772	Bowel Ultrasound Scan Predicts Corticosteroid Failure in Children With Acute Severe Colitis. <b>2020</b> , 71, 46-51		2
771	What is the appropriate cut-off value of CRP to predict endoscopic remission in patients with ulcerative colitis in clinical remission?. <b>2020</b> , 35, 2249-2255		1
770	Role of Ulcerative Colitis Endoscopic Index of Severity (UCEIS) versus Mayo Endoscopic Subscore (MES) in Predicting Patients' Response to Biological Therapy and the Need for Colectomy. <b>2021</b> , 102, 534-545		6
769	The Use of Curcumin as a Complementary Therapy in Ulcerative Colitis: A Systematic Review of Randomized Controlled Clinical Trials. <b>2020</b> , 12,		14
768	JAK Inhibitors: Back to Small Molecules for the Treatment of IBD. <i>Journal of Crohn</i> and <i>Colitis</i> , <b>2020</b> , 14, S711-S712	1.5	1
767	TNF-Alpha Blockers in Inflammatory Bowel Diseases: Practical Recommendations and a User's Guide: An Update. <b>2020</b> , 101 Suppl 1, 16-26		15
766	Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease. <b>2020</b> , 10, CD013256		2
765	Ulcerative Colitis: Making the Diagnosis. <b>2020</b> , 49, 655-669		4
764	Efficacy and safety of acupoint catgut-embedding for ulcerative colitis: A protocol for systematic review and meta-analysis. <b>2020</b> , 99, e22658		
763	Malignancies in Inflammatory Bowel Disease. <b>2020</b> , 101 Suppl 1, 136-145		17
762	A young woman who developed ascending colon cancer 2´years after the onset of ulcerative colitis. <b>2020</b> , 13, 1189-1195		1

761	Clinical evaluation of traditional Chinese medicine on mild active ulcerative colitis: A multi-center, randomized, double-blind, controlled trial. <b>2020</b> , 99, e21903	12
760	Qingchang Huashi granule ameliorates experimental colitis via restoring the dendritic cell-mediated Th17/Treg balance. <b>2020</b> , 20, 291	2
759	Oxidative Stress Markers in Inflammatory Bowel Diseases: Systematic Review. <b>2020</b> , 10,	13
758	Setting up a Virtual Calprotectin Clinic in Inflammatory Bowel Diseases: Literature Review and Nancy Experience. <b>2020</b> , 9,	6
757	COVID-19 and Inflammatory Bowel Disease: Patient Knowledge and Perceptions in a Single Center Survey. <b>2020</b> , 56,	10
756	Observational study on the evaluation of quality of life in patients affected by enteropathic spondyloarthritis. <b>2020</b> , 18, 527-534	
755	Efficacy and safety evaluation of acupoint embedding for patients with ulcerative colitis: A protocol of systematic review and meta-analysis. <b>2020</b> , 99, e21812	О
754	Ulcerative colitis. <b>2020</b> , 6, 74	182
753	Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF?. <b>2020</b> , 7, 517	21
75 <sup>2</sup>	Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis. <b>2020</b> , 9,	6
751	Epstein-Barr virus infection in ulcerative colitis: a clinicopathologic study from a Chinese area. <b>2020</b> , 13, 1756284820930124	1
75°	Endoscopic surveillance of colorectal cancer in inflammatory bowel diseases: a review of the literature. <b>2020</b> , 20, 851-863	2
749	Restorative surgery for ulcerative colitis in the elderly: an analysis of ileal pouch-anal anastomosis procedures from the American College of Surgeons National Surgical Quality Improvement Program. <b>2020</b> ,	3
748	Efficacy and Safety of (Kushen) Based Traditional Chinese Medicine in the Treatment of Ulcerative Colitis: Clinical Evidence and Potential Mechanisms. <b>2020</b> , 11, 603476	19
747	The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study. <b>2020</b> , 9,	10
746	Regular clinical supervision to enhance wellbeing in inflammatory bowel disease specialist nurses: a small pilot study. <b>2020</b> , 18, 36-42	1
745	Identifying environmental risk factors for inflammatory bowel diseases: a Mendelian randomization study. <b>2020</b> , 10, 19273	7
744	Controversies and future of minimally invasive surgery for inflammatory bowel disease. <b>2020</b> , 98, 503-506	

743	Functional Anatomical Changes in Ulcerative Colitis Patients Determine Their Gut Microbiota Composition and Consequently the Possible Treatment Outcome. <b>2020</b> , 13,	5
742	Dysplasia Surveillance in Inflammatory Bowel Disease: A Cohort Study. <b>2021</b> , 28, 97-105	1
741	Infectious Proctitis in Ulcerative Colitis: The Importance of an Accurate Differential Diagnosis. <b>2021</b> , 28, 354-359	
74º	Usefulness of Testing for Fecal Calprotectin in Pediatric Gastroenterology Clinical Practice. <b>2021</b> , 30, 311-319	1
739	High-Definition Chromoendoscopy Superior to High-Definition White-Light Endoscopy in Surveillance of Inflammatory Bowel Diseases in a Randomized Trial. <b>2020</b> , 18, 2101-2107	15
738	Surveillance in inflammatory bowel disease: is chromoendoscopy the only way to go? A systematic review and meta-analysis of randomized clinical trials. <b>2020</b> , 8, E578-E590	10
737	Lizhong decoction ameliorates ulcerative colitis in mice via modulating gut microbiota and its metabolites. <b>2020</b> , 104, 5999-6012	25
736	The use of ICD codes to identify IBD subtypes and phenotypes of the Montreal classification in the Swedish National Patient Register. <b>2020</b> , 55, 430-435	10
735	Indigo Naturalis Alleviates Dextran Sulfate Sodium-Induced Colitis in Rats via Altering Gut Microbiota. <b>2020</b> , 11, 731	20
734	Hydrogen peroxide and disease: towards a unified system of pathogenesis and therapeutics. <b>2020</b> , 26, 41	14
733	Approach to Latent Tuberculosis Infection Screening Before Biologic Therapy in IBD Patients: PPD or IGRA?. <b>2020</b> , 26, 1315-1318	2
732	An Indian national survey of therapeutic drug monitoring with anti-tumor necrosis (TNF) medications in inflammatory bowel disease. <b>2020</b> , 39, 176-185	4
731	High Abundance of Proteobacteria in Ileo-Anal Pouch Anastomosis and Increased Abundance of Fusobacteria Associated with Increased Pouch Inflammation. <b>2020</b> , 9,	2
730	Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases. <b>2020</b> , 9,	7
729	High Frequency of Undiagnosed Psychiatric Disorders in Inflammatory Bowel Diseases. 2020, 9,	9
728	A disease-specific decline of the relative abundance of Bifidobacterium in patients with autoimmune hepatitis. <b>2020</b> , 51, 1417-1428	20
727	Review article: withdrawal of 5-aminosalicylates in inflammatory bowel disease. <b>2020</b> , 52, 73-84	11
726	Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysis. <b>2020</b> , 15, e0233781	15

725	SFED recommendations for IBD endoscopy during COVID-19 pandemic: Italian and French experience. <b>2020</b> , 17, 507-516	13
724	Inflammatory bowel diseaselssociated neoplasia. 2020, 167-178	
723	Macroscopic examination of surgically resected specimens in inflammatory bowel disease. 2020, 571-581	
722	Remote ischemic conditioning in active ulcerative colitis: An explorative randomized clinical trial. <b>2020</b> , 10, 9537	2
721	Scarless, entirely laparoscopic panproctocolectomy and extrasphincteric dissection with perineal extraction of the specimen for cancer of the anorectal junction - a video vignette. <b>2020</b> , 22, 1780-1782	O
720	Heat shock transcription factor 2 predicts mucosal healing and promotes mucosal repair of ulcerative colitis. <b>2020</b> , 55, 677-686	1
719	Irish data on the safety and efficacy of vedolizumab in the treatment of inflammatory bowel disease. <b>2020</b> , 55, 786-794	О
718	The diagnostic role and clinical association of serum proteinase 3 anti-neutrophil cytoplasmic antibodies in Chinese patients with inflammatory bowel disease. <b>2020</b> , 55, 806-813	2
717	Cuffitis: is an endoscopic approach possible?. <b>2020</b> , 8, E544-E547	1
716	Vitamin D levels in IBD: a randomised trial of weight-based versus fixed dose vitamin D supplementation. <b>2020</b> , 55, 671-676	1
715	Impact of fecal microbiota transplantation on chronic recurrent pouchitis in ulcerative colitis with ileo-anal anastomosis: study protocol for a prospective, multicenter, double-blind, randomized, controlled trial. <b>2020</b> , 21, 455	2
714	The impact of COVID-19 pandemic in the colorectal cancer prevention. <b>2020</b> , 35, 1951-1954	31
713	Segmental colectomy for ulcerative colitis: is there a place in selected patients without active colitis? An international multicentric retrospective study in 72 patients. <i>Journal of Crohn</i> and <i>Colitis</i> , <b>2020</b> ,	4
712	Systematic review with meta-analysis: IBD-associated colonic dysplasia prognosis in the videoendoscopic era (1990 to present). <b>2020</b> , 52, 5-19	8
711	ECCO Position Paper: Harmonization of the Approach to Ulcerative Colitis Histopathology. <i>Journal of Crohn</i> and <i>Colitis</i> , <b>2020</b> , 14, 1503-1511	34
710	Improving quality of care in endoscopy of inflammatory bowel disease: can we do better?. <b>2020</b> , 14, 819-828	1
709	Serum adropin levels are reduced in patients with inflammatory bowel diseases. <b>2020</b> , 10, 9264	9
708	Approach to the Patient with Axial Spondyloarthritis and Suspected Inflammatory Bowel Disease. <b>2020</b> , 46, 275-286	1

707	Tacrolimus induces short-term but not long-term clinical response in inflammatory bowel disease. <b>2020</b> , 51, 870-879		4
706	Microbiota intestinale, pre- e probiotici. <b>2020</b> , 22, 1-6		
705	Lymphocyte Activation Gene (LAG)-3 Is Associated With Mucosal Inflammation and Disease Activity in Ulcerative Colitis. <i>Journal of Crohn</i> and Colitis, <b>2020</b> , 14, 1446-1461	1.5	8
704	Ginger in patients with active ulcerative colitis: a study protocol for a randomized controlled trial. <b>2020</b> , 21, 278		3
703	On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases. <b>2020</b> , 9,		16
702	Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study. <b>2020</b> , 51, 852-860		13
701	Crohn's disease. <b>2020</b> , 6, 22		131
700	Pouchitis: Treatment dilemmas at different stages of the disease. <b>2020</b> , 8, 256-262		O
699	The Historical Role and Contemporary Use of Corticosteroids in Inflammatory Bowel Disease. Journal of Crohn and Colitis, <b>2020</b> , 14, 1316-1329	1.5	17
698	Plasma Lysyl-tRNA Synthetase 1 (KARS1) as a Novel Diagnostic and Monitoring Biomarker for Colorectal Cancer. <b>2020</b> , 9,		4
697	Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): ulcerative colitis. <b>2020</b> , 24, 397-419		16
696	A case of refractory chronic pouchitis successfully treated with tofacitinib. <b>2020</b> , 13, 560-563		6
695	Enhancing treatment success in inflammatory bowel disease: Optimising the use of anti-TNF agents and utilising their biosimilars in clinical practice. <b>2020</b> , 52, 1259-1265		5
694	Impact of immune-mediated diseases in inflammatory bowel disease and implications in therapeutic approach. <b>2020</b> , 10, 10731		6
693	The Relationship between C-Reactive Protein/Albumin Ratio and Disease Activity in Patients with Inflammatory Bowel Disease. <b>2020</b> , 2020, 3467419		14
692	Effect of Vedolizumab on Anemia of Chronic Disease in Patients with Inflammatory Bowel Diseases. <b>2020</b> , 9,		1
691	Incidence of Prostate Cancer in Inflammatory Bowel Disease: A Meta-Analysis. 2020, 56,		3
690	Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review. <b>2020</b> , 20, 211		6

689	The role of fecal calprotectin in the diagnosis of acute pouchitis following IPAA for ulcerative colitis: a systematic clinical review. <b>2020</b> , 35, 1619-1628	3
688	Ultrasonographic and clinical assessment of peripheral enthesitis and arthritis in an Italian cohort of inflammatory bowel disease patients. <b>2020</b> , 50, 436-443	2
687	Impact of pain associated with the subcutaneous administration of adalimumab. 2020, 43, 9-13	О
686	Targeting NF- <b>B</b> pathway for treating ulcerative colitis: comprehensive regulatory characteristics of Chinese medicines. <b>2020</b> , 15, 15	37
685	Idiopathic acute pancreatitis in patients with inflammatory bowel disease: A multicenter cohort study. <b>2020</b> , 20, 331-337	4
684	Ulcerative Colitis and Cytomegalovirus Infection: From A to Z. <i>Journal of Crohn</i> and <i>Colitis</i> , <b>2020</b> , 14, 1162-1171	14
683	Editorial: establishing a joint approach to a common problem for gastroenterologists. <b>2020</b> , 51, 306-307	О
682	The Management of the Hospitalized Ulcerative Colitis Patient: the Medical-Surgical Conundrum. <b>2020</b> , 22, 11	8
681	Preconception counseling of females with inflammatory bowel disease. <b>2020</b> , 44-45, 101666	О
680	Gastrointestinal Microbiome - What We Need to Know in Clinical Practice. <b>2020</b> , 27, 336-351	7
679	Tailoring Biologic or Immunomodulator Treatment Withdrawal in Inflammatory Bowel Disease. <b>2019</b> , 6, 302	6
678	Inflammatory bowel disease (IBD) position statement of the Italian Society of Colorectal Surgery (SICCR): general principles of IBD management. <b>2020</b> , 24, 105-126	22
677	Impact of pain associated with the subcutaneous administration of adalimumab. 2020, 43, 9-13	8
676	Positioning Therapies in Ulcerative Colitis. <b>2020</b> , 18, 1280-1290.e1	30
675	Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab. <b>2020</b> , 9,	3
674	Long-term outcome of patients with acute severe ulcerative colitis responding to intravenous steroids. <b>2020</b> , 51, 1096-1104	9
673	Risk of colorectal cancer in a population-based study 20 years after diagnosis of ulcerative colitis: results from the IBSEN study. <b>2020</b> , 7, e000361	7
672	Peroxisome Elevation Induces Stem Cell Differentiation and Intestinal Epithelial Repair. <b>2020</b> , 53, 169-184.e1	1 11

671	Can a transition clinic bridge the gap between paediatric and adult inflammatory bowel disease care models?. <b>2020</b> , 52, 516-527		4
670	Inter-Observer Agreement of a New Endoscopic Score for Ulcerative Colitis Activity: Preliminary Experience. <b>2020</b> , 10,		1
669	A Survey Study of Gastroenterologists' Views on Dysplasia Surveillance and Chromoendoscopy in IBD. <b>2020</b> , 26, e59-e61		2
668	Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period. <b>2020</b> , 5, 598-606		63
667	Quality of colonoscopy preparation in patients with inflammatory bowel disease: retrospective analysis of 348 colonoscopies. <b>2020</b> , 48, 300060520903654		4
666	Development of Mucosal PNAd and MAdCAM-1 Venules during Disease Course in Ulcerative Colitis. <b>2020</b> , 9,		3
665	Endoscopic treatment of pouch inlet and afferent limb strictures: stricturotomy vs. balloon dilation. <b>2021</b> , 35, 1722-1733		8
664	Transcriptional Signatures That Define Ulcerative Colitis in Remission. <b>2021</b> , 27, 94-105		10
663	Influence of Severe Vitamin D Deficiency on the Clinical Course of Inflammatory Bowel Disease. <b>2021</b> , 66, 587-596		10
662	Improvement of Fatigue and Quality of Life in Patients with Quiescent Inflammatory Bowel Disease Following a Personalized Exercise Program. <b>2021</b> , 66, 597-604		4
661	FDG-PET-CT Enterography Helps Determine Clinical Significance of Suspected Ileocecal Thickening: A Prospective Study. <b>2021</b> , 66, 1620-1630		2
660	A Prospective Multicenter Study on the Prevalence of Fructose Malabsorption in Patients with Chronic Inflammatory Bowel Disease. <b>2021</b> , 102, 397-403		O
659	A 1-Year Cross-sectional Inflammatory Bowel Disease Surveillance Colonoscopy Cohort Comparing High-definition White Light Endoscopy and Chromoendoscopy. <b>2021</b> , 27, 594-602		2
658	Risk of Late Postoperative Recurrence of Crohn's Disease in Patients in Endoscopic Remission After Ileocecal Resection, Over 10 Years at Multiple Centers. <b>2021</b> , 19, 1218-1225.e4		4
657	Variability in the Distribution of Histological Disease Activity in the Colon of Patients with Ulcerative Colitis. <i>Journal of Crohn</i> and Colitis, <b>2021</b> , 15, 603-608	1.5	2
656	Intramucosal Poorly Differentiated Adenocarcinomas Detected in a Patient with Long-Standing Ulcerative Colitis. <b>2020</b> , 13, 1176-1184		
655	The Risk of Extraintestinal Cancer in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis of Population-based Cohort Studies. <b>2021</b> , 19, 1117-1138.e19		11
654	Optimization of infliximab therapy in inflammatory bowel disease using a dashboard approach-an Indian experience. <b>2021</b> , 77, 55-62		5

653	Use of complementary and alternative medicine and low quality of life associate with the need for psychological and psychotherapeutic interventions in inflammatory bowel disease. <b>2021</b> , 9, 72-81	1
652	An endoscopic treatment strategy for superficial tumors in patients with ulcerative colitis. <b>2021</b> , 36, 498-506	10
651	Dysplastic Progression to Adenocarcinoma is Equivalent in Ulcerative Colitis and Crohn's Disease.  Journal of Crohn and Colitis, 2021, 15, 24-34	5
650	Extraintestinal Manifestations in Patients with Inflammatory Bowel Disease: Study Based on the ENEIDA Registry. <b>2021</b> , 66, 2014-2023	9
649	Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology practice recommendations for medical management and monitoring of inflammatory bowel disease in Asia. <b>2021</b> , 36, 637-645	9
648	Point-of-Care Ultrasound in Inflammatory Bowel Disease. <i>Journal of Crohn</i> and Colitis, <b>2021</b> , 15, 143-151.5	6
647	Multicenter Validation of the DETAIL Questionnaire for the Screening of Spondyloarthritis in Patients With Inflammatory Bowel Diseases. <b>2021</b> , 48, 179-187	О
646	Characterization of inflammatory bowel disease in Colombia: Results of a national register. <b>2021</b> , 86, 153-162	3
645	IL6 genetic variants haplotype is associated with susceptibility and disease activity but not with therapy response in patients with inflammatory bowel disease. <b>2021</b> , 36, 383-393	O
644	The Course of Ulcerative Colitis After Pediatric Liver Transplantation for Sclerosing Cholangitis. <b>2021</b> , 53, 244-249	O
643	Surface-enhanced Raman scattering for the diagnosis of ulcerative colitis: will it change the rules of the game?. <b>2021</b> , 413, 827-838	5
642	Exploring the Potential Mechanism of Guchang Zhixie Wan for Treating Ulcerative Colitis by Comprehensive Network Pharmacological Approaches and Molecular Docking Validation as Well as Cell Experiments. <b>2021</b> , 18, e2000810	7
641	Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study. <b>2021</b> , 9, 507-516	O
640	Genomic Landscape of Early-stage Colorectal Neoplasia Developing From the Ulcerative Colitis Mucosa in the Japanese Population. <b>2021</b> , 27, 686-696	2
639	Medical therapy versus surgery in moderate-to-severe ulcerative colitis. <b>2021</b> , 53, 403-408	3
638	Inflammatory bowel disease course in liver transplant versus non-liver transplant patients for primary sclerosing cholangitis: LIVIBD, an IG-IBD study. <b>2021</b> , 53, 712-716	2
637	Finding a Needle in the Haystack? Defining the Role of Random Biopsies in IBD Dysplasia Surveillance. <b>2021</b> , 27, 787-790	
636	Histological scores in inflammatory bowel disease. <b>2021</b> , 22, 9-22	7

635	Colorectal cancer in Crohn's colitis is associated with advanced tumor invasion and a poorer survival compared with ulcerative colitis: a retrospective dual-center study. <b>2021</b> , 36, 141-150	3
634	Chronisch-entzfidliche Darmerkrankungen (CED). <b>2021</b> , 301-336	
633	Intestinal Ultrasound to Assess Disease Activity in Ulcerative Colitis: Development of a novel UC-Ultrasound Index. <i>Journal of Crohn</i> and Colitis, <b>2021</b> , 15, 1264-1271	4
632	Inflammatory Bowel Disease and Risk of Major Bleeding During Anticoagulation for Venous Thromboembolism. <b>2021</b> , 27, 1773-1783	2
631	Advanced Colonoscopy Techniques in Inflammatory Bowel Diseases. <b>2021</b> , 1-23	
630	Identification of Novel Population-Specific Cell Subsets in Chinese Ulcerative Colitis Patients Using Single-Cell RNA Sequencing. <b>2021</b> , 12, 99-117	4
629	Bowel ultrasound enhances predictive value based on clinical indicators: a scoring system for moderate-to-severe endoscopic activities in patients with ulcerative colitis. <b>2021</b> , 14, 17562848211030050	0
628	Predicting Outcome in Acute Severe Colitis-Controversies in Clinical Practice in 2021. <i>Journal of Crohn</i> and Colitis, <b>2021</b> , 15, 1211-1221	5
627	Pouchitis in inflammatory bowel disease: a review of diagnosis, prognosis, and treatment. <b>2021</b> , 19, 1-11	6
626	Infliximab is more effective than cyclosporine as a rescue therapy for acute severe ulcerative colitis: a retrospective single-center study. <b>2021</b> , 34, 370-377	1
625	ECCO Topical Review Optimising Reporting in Surgery, Endoscopy, and Histopathology. <i>Journal of Crohn</i> and Colitis, <b>2021</b> , 15, 1089-1105	6
624	Young age and short duration of the disease are associated with more frequent relapses in inflammatory bowel disease patients. <b>2021</b> , 94, 43-47	
623	Update on the therapeutic management of patients with either psoriatic arthritis or ulcerative colitis: focus on the JAK inhibitor tofacitinib. <b>2021</b> , 13, 1759720X20977777	4
622	Real-World Experience of Endoscopic Submucosal Dissection for Ulcerative Colitis-Associated Neoplasia. <b>2021</b> , 6, 70-77	3
621	The Usefulness of Serum Vitamin D Levels in the Assessment of IBD Activity and Response to Biologics. <b>2021</b> , 13,	5
620	Symptoms of anxiety/depression is associated with more aggressive inflammatory bowel disease. <b>2021</b> , 11, 1440	8
619	Increased Severity of Ulcerative Colitis in the Terminal Phase of the Metabolic Syndrome. <b>2021</b> , 254, 171-182	0
618	Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease. <b>2021</b> , 81, 333-347	4

617	Efficacy of Oral, Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis:  Systematic Review and Network Meta-analysis. <i>Journal of Crohn</i> and Colitis, <b>2021</b> , 15, 1184-1196	7
616	Colon Cancer Screening and Surveillance in the IBD Patient. <b>2021</b> , 245-263	
615	Ulcerative Colitis Diagnosis and Management: Past, Present, and Future Directions. 2021, 61-88	O
614	A Reliability Study: Strong Inter-Observer Agreement of an Expert Panel for Intestinal Ultrasound in Ulcerative Colitis. <i>Journal of Crohn</i> and <i>Colitis</i> , <b>2021</b> , 15, 1284-1290	7
613	The pouch behaving badly: management of morbidity after ileal pouch-anal anastomosis. <b>2021</b> , 23, 1193-1204	<b>1</b> 1
612	Computational Learning of microRNA-Based Prediction of Pouchitis Outcome After Restorative Proctocolectomy in Patients With Ulcerative Colitis. <b>2021</b> , 27, 1653-1660	2
611	Challenges in Crohn's Disease Management after Gastrointestinal Cancer Diagnosis. 2021, 13,	O
610	Discriminant equation using mucosally expressed cytokines and transcription factor for making definite diagnosis of inflammatory bowel disease unclassified. <b>2021</b> , 21, 73	
609	High Prevalence of Ultrasound Verified Enthesitis in Patients With Inflammatory Bowel Disease With or Without Spondylarthritis. <b>2021</b> , 8, 637459	O
608	Effectiveness and Safety of Nonmedical Switch From Adalimumab Originator to SB5 Biosimilar in Patients With Inflammatory Bowel Diseases: Twelve-Month Follow-Up From the TABLET Registry. <b>2021</b> ,	6
607	Cost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in Spain. <b>2021</b> , 1-11	1
606	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of abdominal ultrasound in inflammatory bowel disease. <b>2021</b> , 44, 158-174	
605	How Do I Diagnose and Manage Ileal Pouch Disorders?. <b>2021</b> , 116, 621-624	3
604	Serological markers facilitate the diagnosis of Crohn's disease. <b>2021</b> , 133, 286-290	1
603	Long-term cost and complications of surgery in patients with ulcerative colitis: a claims data analysis. <b>2021</b> , 36, 831-840	
602	The Role of Organoids as a Novel Platform for Modeling of Inflammatory Bowel Disease. <b>2021</b> , 9, 624045	1
601	Age at Diagnosis Is Determinant for the Outcome of Inflammatory Bowel Disease: Is It a Myth?. <b>2021</b> , 12, e00309	O
600	Viral Infections, the Microbiome, and Probiotics. <b>2020</b> , 10, 596166	17

599	Inflammatory bowel disease and SARS-CoV-2 pandemic: current knowledge and recommendations. <b>2021</b> , 56, 656-660		
598	5-Aminosalicylic acid inhibits stem cell function in human adenoma-derived cells: implications for chemoprophylaxis in colorectal tumorigenesis. <b>2021</b> , 124, 1959-1969		3
597	Human Cytomegalovirus and Epstein-Barr virus specific immunity in patients with ulcerative colitis. <b>2021</b> , 21, 379-388		1
596	Advances in the optimization of therapeutic drug monitoring using serum, tissue and faecal anti-tumour necrosis factor concentration in patients with inflammatory bowel disease treated with TNF-Hantagonists. <b>2021</b> , 21, 539-548		3
595	Acute severe ulcerative colitis: management advice for internal medicine and emergency physicians. <b>2021</b> , 16, 1433-1442		2
594	Antioxidant Therapy in Inflammatory Bowel Diseases. <b>2021</b> , 10,		12
593	How to manage inflammatory bowel disease during the COVID-19 pandemic: A guide for the practicing clinician. <b>2021</b> , 27, 1022-1042		11
592	A Rare Autoinflammatory Syndrome Involving Acute Severe Ulcerative Colitis Combined With Iritis. <b>2021</b> , 27, e83-e86		
591	Potential problems of partial resection for colitis-associated cancer in a patient with ulcerative colitis: case report. <b>2021</b> , 2021, rjab086		
590	Drug development for ulcerative proctitis: current concepts. <b>2021</b> , 70, 1203-1209		1
589	Validated Indices for Histopathologic Activity Predict Development of Colorectal Neoplasia in Ulcerative Colitis. <i>Journal of Crohn</i> and Colitis, <b>2021</b> , 15, 1481-1490	1.5	1
588	Ulcerative colitis: nutritional habits as the disease risk factor. <b>2021</b> , 10,		
587	Clinical and Demographic Profile of Inflammatory Bowel Disease Patients in a Reference Center of Sö Paulo, Brazil. <b>2021</b> , 14, 91-102		O
586	Role of Oxidative Stress and Inflammatory Cytokines (TNF-land IL-6) in Acetic Acid-Induced Ulcerative Colitis in Rats: Ameliorated by. <b>2021</b> , 11,		O
585	Distinct transcriptomic signature of mRNA and microRNA in ulcerative colitis and irritable bowel syndrome.		1
5 <sup>8</sup> 4	Is there a standardized practice for the development of international ulcerative colitis and Crohn's disease treatment guidelines?. <b>2021</b> , 9, 408-417		O
583	Recurrent myocarditis in a patient with active ulcerative colitis: a case report and review of the literature. <b>2021</b> , 8,		2
582	The Role of TNF-Hand Anti-TNF-Hagents during Preconception, Pregnancy, and Breastfeeding. <b>2021</b> , 22,		10

581	Possible Earlier Diagnosis of Ulcerative Colitis-Associated Neoplasia: A Retrospective Analysis of Interval Cases during Surveillance. <b>2021</b> , 10,	3
580	Pregnancy in Inflammatory Bowel Disease: Experience of a Chilean cohort. <b>2021</b> , 44, 277-285	
579	Acceptance and Perceived Control are Independently Associated With Quality of Life in Inflammatory Bowel Disease: Introduction of a New Segmentation Model. <i>Journal of Crohn</i> and Colitis, 2021, 15, 1837-1845	0
578	Colonic Strictures in Inflammatory Bowel Disease: Epidemiology, Complications, and Management.  Journal of Crohns and Colitis, 2021, 15, 1766-1773	1
577	Genetic Pathogenesis of Inflammation-Associated Cancers in Digestive Organs. 2021, 10,	1
576	Budesonide MMX in the Treatment of Ulcerative Colitis: Current Perspectives on Efficacy and Safety. <b>2021</b> , 17, 285-292	1
575	An MSCT-based radiomics nomogram combined with clinical factors can identify Crohn's disease and ulcerative colitis. <b>2021</b> , 9, 572	2
574	Residual Short-Segment Distal Inflammation Has No Significant Impact on the Major Relapse of Extensive Ulcerative Colitis. <b>2021</b> ,	2
573	Anal Squamous Cell Carcinoma in Ulcerative Colitis: Can Pouches Withstand Traditional Treatment Protocols?. <b>2021</b> , 64, 1106-1111	О
572	Pregnancy in inflammatory bowel disease: Experience of a Chilean cohort. <b>2021</b> , 44, 277-285	
571	Patients' real-world experience with inflammatory bowel disease: A cross-sectional survey in tertiary care centres from the GETAID group. <b>2021</b> , 53, 434-441	
570	Characterization of inflammatory bowel disease in Colombia: Results of a national register. <b>2021</b> , 86, 153-162	1
569	DNA hypo-methylation facilitates anti-inflammatory responses in severe ulcerative colitis. <b>2021</b> , 16, e0248905	51
568	Real-World Incidence of Suboptimal Response to Anti-Tumor Necrosis Factor Therapy for Ulcerative Colitis: A Nationwide Population-Based Study. <b>2021</b> , 15, 867-877	O
567	Combined endocytoscopy with pit pattern diagnosis in ulcerative colitis-associated neoplasia: Pilot study. <b>2021</b> ,	4
566	Altered Gut Microbial Metabolism of Essential Nutrients in Primary Sclerosing Cholangitis. <b>2021</b> , 160, 1784-1798.e0	17
565	Peritoneal Tuberculosis during Infliximab Treatment in a Patient with Ulcerative Colitis Despite a Negative Quantiferon Test. <b>2021</b> , 10,	О
564	Compound Sophorae Decoction: treating ulcerative colitis by affecting multiple metabolic pathways. <b>2021</b> , 19, 267-283	О

563	Prognostic Factors for Advanced Colorectal Neoplasia in Inflammatory Bowel Disease: Systematic Review and Meta-analysis. <b>2021</b> , 160, 1584-1598	26
562	BBG enhances OLT1177-induced NLRP3 inflammasome inactivation by targeting P2X7R/NLRP3 and MyD88/NF- <b>B</b> signaling in DSS-induced colitis in rats. <b>2021</b> , 270, 119123	16
561	Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. <b>2021</b> , 56, 489-526	40
560	How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group. <b>2021</b> , 12, 656362	18
559	Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study. <b>2021</b> , 56, 560-569	4
558	A new approach to predict ulcerative colitis activity through standard clinical <b>B</b> iological parameters using a robust neural network model. 1	2
557	Clinicopathologic Characteristics and Neoplasia Risk of Colorectal Inflammatory Polyposis in Inflammatory Bowel Disease. <b>2021</b> ,	О
556	Treatment of acute severe ulcerative colitis using accelerated infliximab regimen based on infliximab trough level: A case report. <b>2021</b> , 9, 3219-3226	
555	The IL23-IL17 Immune Axis in the Treatment of Ulcerative Colitis: Successes, Defeats, and Ongoing Challenges. <b>2021</b> , 12, 611256	10
554	Response to Anti-41 Blockade in Patients With Ulcerative Colitis Is Associated With Distinct Mucosal Gene Expression Profiles at Baseline. <b>2021</b> ,	2
553	The Fate of Unifocal Versus Multifocal Low-Grade Dysplasia at the Time of Colonoscopy in Patients With IBD. <b>2021</b> , 64, 1364-1373	0
552	Chronic abdominal pain, Gastroenterologist approach. 2021,	
551	Faecal Calprotectin in Assessment of Mucosal Healing in Adults with Inflammatory Bowel Disease: A Meta-Analysis. <b>2021</b> , 10,	7
550	Effect of golimumab on health-related quality of life, other patient-reported outcomes and healthcare resource utilization in patients with moderate-to-severe ulcerative colitis: a real-world multicenter, noninterventional, observational study in Greece. 2021,	1
549	Multicentre derivation and validation of a colitis-associated colorectal cancer risk prediction web tool. <b>2021</b> ,	3
548	Clinical Significance of Residual Nonrectal Inflammation in Ulcerative Colitis Patients in Clinical Remission. <b>2021</b> , 15, 401-409	2
547	Evaluation of the efficacy of MMX mesalazine therapy for moderate ulcerative colitis. <b>2021</b> , 113-123	1
546	Probiotics and gut health. <b>2021</b> ,	1

545	The rationale for selenium supplementation in inflammatory bowel disease: A mechanism-based point of view. <b>2021</b> , 85, 111153	11
544	Clinical aspects and prognosis of patients with inflammatory bowel disease associated with autoimmune liver diseases. <b>2021</b> ,	1
543	Histological Inflammation in the Endoscopically Uninflamed Mucosa is Associated With Worse Outcomes in Limited Ulcerative Colitis. <b>2021</b> ,	2
542	Elevated systemic immune inflammation index level is associated with disease activity in ulcerative colitis patients. <b>2021</b> , 517, 122-126	4
541	The long-term incidence of dysplasia and colorectal cancer in a Crohn's colitis population-based cohort. <b>2021</b> , 23, 2399-2406	0
540	Systematic evaluation of the diagnostic approach of inflammatory bowel disease guidelines. <b>2021</b> , 75, e14365	O
539	Is Ustekinumab Effective in Refractory Crohn's Disease of the Pouch and Chronic Pouchitis? A Systematic Review. <b>2021</b> , 1	О
538	Endoscopic submucosal dissection is safe and feasible, allowing for ongoing surveillance and organ preservation in patients with inflammatory bowel disease. <b>2021</b> , 23, 2100-2107	3
537	Predicting Colorectal Cancer Occurrence in IBD. <b>2021</b> , 13,	3
536	Characterization and prevalence of extraintestinal manifestations in a cohort of patients with inflammatory intestinal disease in Medellin, Colombia. <b>2021</b> , 44, 398-404	
535	Serum Levels of Fibroblast Growth Factor 19 Correlate with the Severity of Diarrhea and Independently from Intestinal Inflammation in Patients with Inflammatory Bowel Disease or Microscopic Colitis. <b>2021</b> , 32, 374-381	O
534	Berwachung und Management von Dysplasien bei chronisch-entzfidlichen Darmerkrankungen. <b>2021</b> , 16, 267-277	
533	Recommendations of the Spanish Working Group on Crohn's disease and Ulcerative Colitis (Grupo Espa <del>ô</del> l de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa - GETECCU) on dysplasia screening in inflammatory bowel disease patients. <b>2021</b> , 44, 435-447	0
532	The comparison of the three assays for determination of fecal calprotectin in inflammatory bowel disease. <b>2021</b> , 31, 020707	1
531	Management of patients with Intestinal Bowel Disease and COVID-19: A review of current evidence and future perspectives. <b>2021</b> ,	0
530	Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: A GETAID cohort. <b>2021</b> , 54, 312-319	1
529	Perception of cancer risk and management practice for colitis-associated dysplasia is influenced by colonoscopy experience and workplace results of an international clinician survey. <i>Journal of Crohn</i> and Colitis, <b>2021</b> ,	1.5 1
528	Recommendations of the Spanish Working Group on Crohn disease and Ulcerative Colitis (Grupo Espa <del>ô</del> l de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) on dysplasia screening	

527	Characterization and prevalence of extraintestinal manifestations in a cohort of patients with inflammatory intestinal disease in Medellin, Colombia. <b>2021</b> , 44, 398-404	1
526	Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the Global Interventional Inflammatory Bowel Disease Group. <b>2021</b> , 6, 482-497	9
525	Chinese consensus on diagnosis and treatment in inflammatory bowel disease (2018, Beijing). <b>2021</b> , 22, 298-317	10
524	Practice pattern variability among gastroenterologists in colorectal cancer surveillance and management of colorectal dysplasia in inflammatory bowel disease. <b>2021</b> , 22, 463-472	О
523	Comparing the clinical application values of the Degree of Ulcerative Colitis Burden of Luminal Inflammation (DUBLIN) score and Ulcerative Colitis Endoscopic Index of Severity (UCEIS) in patients with ulcerative colitis <b>2021</b> , 9, 533-542	1
522	Interrater reliability of the assessment of disease activity by gastrointestinal ultrasound in a prospective cohort of patients with inflammatory bowel disease. <b>2021</b> , 33, 1280-1287	О
521	[Position paper on endoscopic reporting in IBD]. <b>2021</b> , 59, 1091-1109	1
520	Twelve-week peptide-based formula therapy may be effective in inducing remission of active Crohn disease among women who are pregnant or preparing for pregnancy. <b>2021</b> ,	1
519	Ulcerative colitis-related postoperative enteritis treated with anti-tumor necrosis factor therapy: two case reports and a literature review. <b>2021</b> , 14, 1396-1403	O
518	Computed tomography enterocolongraphy in assessment of degree of ulcerative colitis activity. <b>2021</b> , 75, e14626	1
517	[22 years old woman presenting with lower abdominal pain and fecal blood: Preparation for the medical specialist examination: part 86]. <b>2021</b> , 62, 561-564	
516	Randomised clinical trial: Efficacy and safety of Qing-Chang-Hua-Shi granules in a multicenter, randomized, and double-blind clinical trial of patients with moderately active ulcerative colitis. <b>2021</b> , 139, 111580	2
515	Patients' perceptions of surgery for inflammatory bowel disease. <b>2021</b> , 23, 2690-2698	
514	Colorectal Cancer Prevention in Inflammatory Bowel Disease: A Systematic Analysis of the Overall Quality of Guideline Recommendations. <b>2021</b> ,	o
513	Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases. <b>2021</b> , 56, 1040-1048	3
512	The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surgical Management of Ulcerative Colitis. <b>2021</b> , 64, 783-804	2
511	Periodic Colonoscopies Are Associated with Improved Survival and Prognosis of Colorectal Cancer in Ulcerative Colitis. <b>2021</b> , 1	О
510	Efficacy and tolerability of very low-volume bowel preparation in patients with inflammatory bowel diseases. <b>2021</b> , 33, 977-982	О

## (2021-2021)

509	[Quality management in the field of gastroenterology - Proposals of the Quality Commission of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) for Outpatient and Inpatient Quality Assurance]. <b>2021</b> , 59, 665-676	
508	Pouchitis: Clinical Features, Diagnosis, and Treatment. <b>2021</b> , 14, 3871-3879	2
507	Cytomegalovirus Limited to the Rectum in an Immunosuppressed IBD Patient. 2021, 27, e154-e155	
506	Aggressive Colorectal Cancer in an Inflammatory Bowel Disease Patient following Treatment with Vedolizumab: A Case Report. 1-6	1
505	Comparison of 1-Year Colectomy Risk Between the US and Korean Patients with Acute Severe Ulcerative Colitis: A Propensity Score Matching Analysis. <b>2021</b> , 1	
504	Prevalence of Microscopic Colitis in Diarrhea-predominant Irittable Bowel Syndrome Patients: Cohort Study From Upper Egypt. <b>2021</b> ,	2
503	Laparoscopic completion proctectomy and pouch with lengthening techniques - a video vignette. <b>2021</b> , 23, 1990-1991	
502	Long-term outcomes of infliximab in a real-world multicenter cohort of patients with acute severe ulcerative colitis. <b>2021</b> , 19, 323-331	4
501	The Role of Biomarkers in Surgery for Ulcerative Colitis: A Review. <b>2021</b> , 10,	3
500	Antibiotics in pediatric inflammatory bowel diseases: a systematic review. <b>2021</b> , 15, 891-908	1
499	Germline Alterations in Patients With IBD-associated Colorectal Cancer. 2021,	1
498	Predictive factors of relapse after dose reduction of oral 5-aminosalicylic acid in patients with ulcerative colitis in the remission phase. <b>2021</b> , 16, e0255620	1
497	Risk factors for failure of ileal pouch-anal anastomosis in patients with refractory ulcerative colitis. <b>2021</b> ,	2
496	Real-World Efficacy and Safety Monitoring for Predicting Continuation of Tofacitinib Therapy in Patients with Ulcerative Colitis. <b>2021</b> , 1	1
495	The importance of sarcopenia as a prognostic predictor of the clinical course in acute severe ulcerative colitis patients. <b>2021</b> , 53, 965-971	3
494	Yield and Predictors of Surveillance Colonoscopies in Older Adults With Long-standing Ulcerative Colitis. <b>2021</b> ,	
493	Epidemiology of Colorectal Cancer in Inflammatory Bowel Disease - the Evolving Landscape. <b>2021</b> , 23, 16	4
492	Cross Talk between Gut Microbiota and Intestinal Mucosal Immunity in the Development of Ulcerative Colitis. <b>2021</b> , 89, e0001421	9

491 Artificial intelligence assisted assessment of endoscopic disease activity in inflammatory bowel disease. **2021**, 2, 95-102

490	Reply. <b>2021</b> ,	
489	Resilience as a Mediator of the Association Between Perceived Stigma and Quality of Life Among People With Inflammatory Bowel Disease. <b>2021</b> , 12, 709295	0
488	Biological Treatments in Inflammatory Bowel Disease: A Complex Mix of Mechanisms and Actions. <b>2021</b> , 1, 189-210	1
487	Mobile application to monitor inflammatory bowel disease patients on intravenous biologic treatment: a feasibility study. <b>2021</b> , 56, 1414-1421	0
486	Further research on the clinical relevance of the ulcerative colitis colonoscopic index of severity for predicting 5-year relapse. <b>2021</b> , 36, 2661-2670	2
485	Drug delivery to the inflamed intestinal mucosa - targeting technologies and human cell culture models for better therapies of IBD. <b>2021</b> , 175, 113828	4
484	Translation into Spanish and validation of a short questionnaire to measure the control of inflammatory bowel disease from the patient's perspective: IBD-Control, EII-Control. <b>2021</b> ,	1
483	Prevalence of Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. <b>2021</b> , 161, 1865-1877	2
482	Effectiveness and safety of 1L PEG-ASC preparation for colonoscopy in patients with inflammatory bowel diseases. <b>2021</b> , 53, 1171-1177	O
481	Efficacy of switching from infliximab to golimumab in patients with ulcerative colitis in deep remission. <b>2021</b> , 84, 423-428	
480	Restorative Proctocolectomy: When to Propose and When to Avoid.	
479	5-Aminosalicylic Acid Chemoprevention in Inflammatory Bowel Diseases: Is It Necessary in the Age of Biologics and Small Molecules?. <b>2022</b> , 7, 28-35	0
478	Qingchang Wenzhong Decoction Accelerates Intestinal Mucosal Healing Through Modulation of Dysregulated Gut Microbiome, Intestinal Barrier and Immune Responses in Mice. <b>2021</b> , 12, 738152	3
477	Potential Salivary Markers for Differential Diagnosis of Crohn's Disease and Ulcerative Colitis. <b>2021</b> , 11,	1
476	Incidence of and Risk Factors for Colorectal Strictures in Ulcerative Colitis: A Multicenter Study. <b>2021</b> , 19, 1899-1905.e1	3
475	C3435T Polymorphism of the ABCB1 Gene in Polish Patients with Inflammatory Bowel Disease: A Case-Control and Meta-Analysis Study. <b>2021</b> , 12,	O
474	The association between pre-colectomy thiopurine use and risk of neoplasia after ileal pouch anal anastomosis in patients with ulcerative colitis or indeterminate colitis: a propensity score analysis. <b>2021</b> , 1	1

## (2021-2021)

473	Usefulness of Colon Assessment by Magnetic Resonance Enterography in Pediatric Patients with Inflammatory Bowel Disease-Retrospective Case Series. <b>2021</b> , 10,	1
472	Evidence for the butyrate metabolism as key pathway improving ulcerative colitis in both pediatric and adult patients. <b>2021</b> , 12, 8309-8324	Ο
471	Serum Levels of PCSK9 Are Increased in Patients With Active Ulcerative Colitis Representing a Potential Biomarker of Disease Activity: A Cross-sectional Study. <b>2021</b> ,	0
470	Ulcerative colitis: understanding the impact of ulcerative colitis on everyday life and exploring the unmet needs of patients. <b>2021</b> , 37, 1901-1911	Ο
469	Keratin 1 maintains the intestinal barrier in ulcerative colitis. <b>2021</b> , 43, 1389-1402	Ο
468	Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy. <b>2021</b> ,	
467	Long-term Antibiotic Treatment in Pouchitis-Patterns of Use and Safety. 2021,	2
466	Chronic pouchitis and Crohn's disease of the pouch after ileal pouch-anal anastomosis: Incidence and risk factors. <b>2021</b> , 53, 1128-1135	Ο
465	LncRNA LUCAT1 as a Plasma Biomarker for Assessing Disease Activity in Adult Patients with Crohn's Disease. <b>2021</b> , 2021, 5557357	
464	Effectiveness of a Blended Internet-Based Mindfulness Intervention in Inflammatory Bowel Disease Patients: a Mixed-Methods Non-randomized Controlled Trial. <b>2021</b> , 12, 2767	1
463	AGA Clinical Practice Update on Endoscopic Surveillance and Management of Colorectal Dysplasia in Inflammatory Bowel Diseases: Expert Review. <b>2021</b> , 161, 1043-1051.e4	6
462	MicroRNA expression in inflammatory bowel disease-associated colorectal cancer. <b>2021</b> , 13, 995-1016	3
461	Urotensin II levels in patients with inflammatory bowel disease. <b>2021</b> , 27, 6142-6153	1
460	Anti-tumour necrosis factor tantibodies and circulating lymphocyte phenotypes in inflammatory bowel disease. <b>2021</b> , 100, 108081	
459	A meta-analysis on sleep quality in inflammatory bowel disease. <b>2021</b> , 60, 101518	3
458	Systematic Review and Meta-analysis of Immunomodulator and Biologic Therapies for Treatment of Chronic Pouchitis.	
457	Can fecal calprotectin accurately identify histological activity of ulcerative colitis? A meta-analysis. <b>2021</b> , 14, 1756284821994741	2
456	Comparison of the Mayo Endoscopy Score and the Ulcerative Colitis Endoscopy Index of Severity and the Ulcerative Colitis Colonoscopy Index of Severity. <b>2021</b> , 9, E130-E136	3

455	Clinical usefulness of linked color imaging for evaluation of endoscopic activity and prediction of relapse in ulcerative colitis. <b>2021</b> , 36, 1053-1061	3
454	Validation of claims-based indicators used to identify flare-ups in inflammatory bowel disease. <b>2021</b> , 14, 17562848211004841	
453	Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study. <b>2021</b> , 14, 17562848211023384	4
452	Chinese herbal extract granules combined with 5-aminosalicylic acid for patients with moderately active ulcerative colitis: study protocol for a multicenter randomized double-blind placebo-controlled trial. <b>2021</b> , 22, 55	O
451	The role of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio in ulcerative colitis. <b>2021</b> , 19, 62-70	10
450	The Effect of Lactobacillus casei on Experimental Porcine Inflammatory Bowel Disease Induced by Dextran Sodium Sulphate. <b>2021</b> , 64, 85-90	
449	Molecular Profiling of IBD Subtypes and Therapy Responses. <b>2019</b> , 157-182	1
448	GETECCU 2020 guidelines for the treatment of ulcerative colitis. Developed using the GRADE approach. <b>2020</b> , 43 Suppl 1, 1-57	3
447	Aktualisierte S3-Leitlinie Colitis ulcerosa Living Guideline. <b>2020</b> , 58, e241-e326	6
446	Effect of TrkB-PLC/IP3 pathway on intestinal inflammatory factors and enterocyte apoptosis in mice with colitis. <b>2020</b> , 52, 675-682	4
445	Multidimensional Impact of Mediterranean Diet on IBD Patients. 2021, 27, 1-9	32
444	The Patterns of Use of Medications for Inflammatory Bowel Disease During Pregnancy in the US and Sweden Are Changing. <b>2021</b> , 27, 1427-1434	О
443	To assess the effective and safety of berberine hydrochloride in ulcerative colitis: A protocol for systematic review and meta-analysis. <b>2020</b> , 99, e23482	2
442	Rewiring of the cellular and inter-cellular landscape of the human colon during ulcerative colitis.	12
441	Systematic review with meta-analysis: thiopurines decrease the risk of colorectal neoplasia in patients with inflammatory bowel disease. <b>2018</b> , 47, 318-331	24
440	Increased risks of dental caries and periodontal disease in Chinese patients with inflammatory bowel disease. <b>2020</b> , 70, 227-236	13
439	Potential methods for improving the efficacy of mesenchymal stem cells in the treatment of inflammatory bowel diseases. <b>2020</b> , 92, e12897	4
438	Quyushengxin Formula Causes Differences in Bacterial and Phage Composition in Ulcerative Colitis Patients. <b>2020</b> , 2020, 5859023	4

## (2020-2020)

437	Immunosuppression and Malignant Neoplasms: Risk-Benerit Assessment in Patients with Inflammatory Bowel Disease. <b>2020</b> , 21, e920949	2
436	A practical marker to determining acute severe ulcerative colitis: CRP/albumin ratio. <b>2020</b> , 7, 49-55	5
435	The use of serum calprotectin as a biomarker for inflammatory activity in inflammatory bowel disease. <b>2019</b> , 111, 744-749	7
434	Alterations in the mucosa-associated fungal microbiota in patients with ulcerative colitis. <b>2017</b> , 8, 107577-107	5 <del>585</del> 8
433	Social and demographic characteristics, features of disease course and treatment options of inflammatory bowel disease in Russia: results of two multicenter studies. <b>2018</b> , 46, 445-463	27
432	Budesonide Hn the treatment of ulcerative colitis: real world clinical practice. <b>2019</b> , 47, 505-510	1
431	Steroids and Postoperative Complications in IBD. <b>2019</b> , 20, 1323-1326	2
430	Anti-TNF and Pouch Surgery for Ulcerative Colitis: The Ones who Blame for More Complications?. <b>2019</b> , 20, 1349-1355	2
429	'Treat to Target' in Mild to Moderate Ulcerative Colitis: Evidence to Support this Strategy. <b>2021</b> , 22, 117-125	2
428	Telemonitoring of Crohn's Disease and Ulcerative Colitis (TECCU): Cost-Effectiveness Analysis. <b>2019</b> , 21, e15505	11
427	Serum zonulin in patients with inflammatory bowel disease: a pilot study. 2019, 110, 95-100	35
426	Dendritic cell profiles in the inflamed colonic mucosa predict the responses to tumor necrosis factor alpha inhibitors in inflammatory bowel disease. <b>2018</b> , 52, 443-452	4
425	The Role of Diet in the Pathogenesis and Management of Inflammatory Bowel Disease: A Review. <b>2020</b> , 13,	20
424	Colorectal cancer surveillance in inflammatory bowel disease: Practice guidelines and recent developments. <b>2019</b> , 25, 4148-4157	54
423	Nonalcoholic fatty liver disease in patients with inflammatory bowel disease: Beyond the natural history. <b>2019</b> , 25, 5676-5686	15
422	Metabolic syndrome attenuates ulcerative colitis: Correlation with interleukin-10 and galectin-3 expression. <b>2019</b> , 25, 6465-6482	9
421	Inactive matrix Gla protein is elevated in patients with inflammatory bowel disease. <b>2020</b> , 26, 4866-4877	6
420	Updated bone mineral density status in Saudi patients with inflammatory bowel disease. <b>2020</b> , 26, 5343-5353	1

419	First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. <b>2020</b> , 26, 6710-6769	4
418	Colorectal cancer and dysplasia risk of ulcerative colitis patients in a tertiary referral center in Turkey. <b>2019</b> , 30, 139-147	4
417	Post-colonoscopy colorectal cancer rates in the Swedish IBD and non-IBD population: Something missed or something faster?. <b>2019</b> , 30, 860-862	1
416	Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy-Access to Rapid Treatment (iSTART) approach. <b>2018</b> , 16, 522-528	11
415	Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients. <b>2019</b> , 17, 87-93	3
414	The impact of corticosteroid use on inpatients with inflammatory bowel disease and positive polymerase chain reaction for Clostridium difficile. <b>2019</b> , 17, 244-252	O
413	Real-time data monitoring for ulcerative colitis: patient perception and qualitative analysis. <b>2019</b> , 17, 365-374	6
412	Are Truelove and Witts criteria for diagnosing acute severe colitis relevant for the Indian population? A prospective study. <b>2018</b> , 16, 69-74	7
411	Management of inflammatory bowel disease in older persons: evolving paradigms. 2018, 16, 194-208	15
410	Can vitamin D supplementation help control inflammation in inflammatory bowel disease beyond its classical role in bone health?. <b>2019</b> , 17, 157-159	6
409	Advanced neoplasia detection using chromoendoscopy and white light colonoscopy for surveillance in patients with inflammatory bowel disease. <b>2020</b> , 18, 438-446	1
408	Prevalence and patient awareness of inflammatory bowel disease in Kazakhstan: a cross-sectional study. <b>2020</b> , 18, 430-437	11
407	High mucosal cytomegalovirus DNA helps predict adverse short-term outcome in acute severe ulcerative colitis. <b>2021</b> , 19, 438-447	3
406	Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI). <b>2021</b> , 19, 386-397	5
405	Endoscopic Therapeutic Approach for Dysplasia in Inflammatory Bowel Disease. 2017, 50, 437-445	4
404	Clinical Predictors of Depression among Patients with Inflammatory Bowel Diseases: A Cross-sectional Analytical Study from Oman <b>2022</b> , 37, e352	O
403	Insights into the role of gastrointestinal ultrasound in ulcerative colitis. <b>2021</b> , 14, 17562848211051456	О
402	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of abdominal ultrasound in inflammatory bowel disease. <b>2021</b> , 44, 158-174	

401	Emerging Comorbidities in Inflammatory Bowel Disease: Eating Disorders, Alcohol and Narcotics Misuse. <b>2021</b> , 10,	2
400	Machine Learning Prediction Model for Inflammatory Bowel Disease Based on Laboratory Markers. Working Model in a Discovery Cohort Study. <b>2021</b> , 10,	1
399	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment. <i>Journal of Crohn</i> and <i>Colitis</i> , <b>2021</b> ,	2
398	Editorial commentary on Indian Journal of Gastroenterology-September-October 2021. <b>2021</b> , 1	
397	Extracellular Matrix Components as Diagnostic Tools in Inflammatory Bowel Disease. <b>2021</b> , 10,	2
396	Inflammatory bowel disease manifestations in spondyloarthritis: considerations for the clinician. <b>2021</b> , 17, 1199-1209	O
395	Risk Factors of Cytomegalovirus Reactivation in Ulcerative Colitis Patients: A Meta-Analysis. <b>2021</b> , 11,	2
394	An extremes of phenotype approach confirms significant genetic heterogeneity in patients with ulcerative colitis.	
393	Increased Self-medication with Steroids in Inflammatory Bowel Disease Patients during COVID-19 Pandemic: Time to Optimize Specialized Telemonitoring Services. <b>2021</b> , 11, 103-104	О
392	A Pilot Study of Clinical Evaluation and Formation Mechanism of Irritable Bowel Syndrome-like Symptoms in Inflammatory Bowel Disease Patients in Remission. <b>2021</b> , 27, 612-625	О
391	Lymphocyte-to-Monocyte Ratio as a Marker for Endoscopic Activity in Ulcerative Colitis. <b>2021</b> , 1, 360-368	
390	Leitsymptom. <b>2018</b> , 101-145	
389	Medical Therapy in Stricturing Inflammatory Bowel Diseases. <b>2018</b> , 209-223	
388	Inflammatory bowel disease registries for collection of patient iron parameters in Europe. <b>2018</b> , 24, 1063-107	11
387	DIAGNOSTIC POSSIBILITIES OF FECAL CALPROTECTIN APPLICATION IN PATIENTS WITH INFLAMMATORY DOWEL DISEASES DURING PREGNANCY (literature review and clinical observations). <b>2018</b> , 95-101	
386	Conventional and biological therapy for inflammatory bowel disease. <b>2018</b> , 64, 642-653	1
385	PSC-IBD: specific phenotype of inflammatory bowel disease associated with primary sclerosing cholangitis. <b>2018</b> , 64, 659-664	1
384	Screening for colorectal cancer in patients with inflammatory bowel disease. Should we already perform chromoendoscopy in all our patients?. <b>2018</b> , 10, 322-325	Ο

Therapeutic Management in Ulcerative Colitis. 2018, 15, 61-72  380 Is celiac disease really associated with inflammatory bowel disease?. 2020, 112, 4-6  379 Preventing Colorectal Cancer in Patients with Inflammatory Bowel Diseases: Chemopreventive and Surgical Approaches. 2019, 109-118  378 Appel pour un encadrement plus strict des probiotiques. 2019, N° 1, 37  Conserved transcriptomic profile between mouse and human colitis allows temporal dynamic visualization of IBD-risk genes and unsupervised patient stratification.  376 The Gut Microbiome in Inflammatory Bowel Disease. 2019, 347-377  375 Endoscopy. 2019, 33-42  374 Exposome and Diet. 2019, 281-291
380 Is celiac disease really associated with inflammatory bowel disease?. 2020, 112, 4-6  379 Preventing Colorectal Cancer in Patients with Inflammatory Bowel Diseases: Chemopreventive and Surgical Approaches. 2019, 109-118  378 Appel pour un encadrement plus strict des probiotiques. 2019, N° 1, 37  Conserved transcriptomic profile between mouse and human colitis allows temporal dynamic visualization of IBD-risk genes and unsupervised patient stratification.  376 The Gut Microbiome in Inflammatory Bowel Disease. 2019, 347-377  Endoscopy. 2019, 33-42
Preventing Colorectal Cancer in Patients with Inflammatory Bowel Diseases: Chemopreventive and Surgical Approaches. 2019, 109-118  Appel pour un encadrement plus strict des probiotiques. 2019, N° 1, 37  Conserved transcriptomic profile between mouse and human colitis allows temporal dynamic visualization of IBD-risk genes and unsupervised patient stratification.  The Gut Microbiome in Inflammatory Bowel Disease. 2019, 347-377  Endoscopy. 2019, 33-42
Surgical Approaches. 2019, 109-118  378 Appel pour un encadrement plus strict des probiotiques. 2019, N° 1, 37  Conserved transcriptomic profile between mouse and human colitis allows temporal dynamic visualization of IBD-risk genes and unsupervised patient stratification.  376 The Gut Microbiome in Inflammatory Bowel Disease. 2019, 347-377  Endoscopy. 2019, 33-42
Conserved transcriptomic profile between mouse and human colitis allows temporal dynamic visualization of IBD-risk genes and unsupervised patient stratification.  The Gut Microbiome in Inflammatory Bowel Disease. 2019, 347-377  Endoscopy. 2019, 33-42
visualization of IBD-risk genes and unsupervised patient stratification.  The Gut Microbiome in Inflammatory Bowel Disease. 2019, 347-377  Endoscopy. 2019, 33-42
375 Endoscopy. <b>2019</b> , 33-42
374 Exposome and Diet. <b>2019</b> , 281-291
373 Anastomose ilbanale. <b>2019</b> , 13, 35-38
Presence of pseudopolyps in ulcerative colitis is associated with a higher risk for treatment escalation. <b>2019</b> , 32, 168-173
Primary Sclerosing Cholangitis Overlapping with IBD. <b>2019</b> , 191-204
370 Chronic Inflammatory Bowel Disease in Remission: Mucosal Neoplasias. <b>2019</b> , 291-305
DIAGNOSTIC VALUE OF LABORATORY AND FECAL BIOMARKERS FOR DETERMINING THE ACTIVITY OF ULCERATIVE COLITIS. <b>2019</b> , 4, 158
368 Constipation. <b>2019</b> , 311-325
367 Cancer. <b>2019</b> , 205-213
366 MicroRNAs and Inflammatory Bowel Disease. <b>2019</b> , 203-230 o

365 Surgical Approach to the Older Ulcerative Colitis Patient. **2019**, 279-284

364	Clinical Risk Factors: Lessons from Epidemiology. <b>2019</b> , 9-22	
363	Indian guidelines on imaging of the small intestine in Crohn's disease: A joint Indian Society of Gastroenterology and Indian Radiology and Imaging Association consensus statement. <b>2019</b> , 29, 111-132	O
362	Vedolizumab en tratamiento de colitis ulcerativa refractaria asociada con psoriasis: reporte de caso. <b>2019</b> , 34, 79	
361	Enfermedad inflamatoria intestinal: aspectos prüticos para el mülico de familia. <b>2019</b> , 26, 195-204	
360	The use of fecal calprotectin in monitoring activity of inflammatory bowel diseases. <b>2019</b> , 91, 53-61	5
359	Inpatient Management of Acute Severe Ulcerative Colitis. 2019, 14, 766-773	5
358	Telemonitoring of Crohn® Disease and Ulcerative Colitis (TECCU): Cost-Effectiveness Analysis (Preprint).	
357	Vitamin D supplementation dose needs to be higher in patients with inflammatory bowel disease: interventional study. <b>2019</b> , 65, 470-474	5
356	Chirurgie digestive chez des patients atteints de maladies inflammatoires chroniques de l <b>i</b> ntestin sous biothfapies. <b>2019</b> , 5, 248-250	
355	Inflammatory bowel disease and the importance of probiotics treatment. 2019, 16, 215-219	
354	Multi-centre derivation and validation of a colitis-associated colorectal cancer risk prediction web-tool.	
353	Patient's profiling for therapeutic management of inflammatory bowel disease: a tailored approach. <b>2020</b> , 14, 765-773	3
352	New insights in Ulcerative Colitis Associated Gut Microbiota in South American Population: Akkermansia and Collinsella, two distinctive genera found in Argentine subjects.	
351	Colon Cancer in Patients with Crohn Disease and Diabetes Mellitus. 2020, 26, 150-153	
350	Le recours ^la chirurgie est-il parfois trop tardif dans le cadre des MICI ?. <b>2020</b> , 14, 159-166	
349	Features of intestinal microbiota in ulcerative colitis. <b>2020</b> , 78-85	
348	Delivery Mode after Ileal Pouch-Anal Anastomosis among Pregnant Women with Ulcerative Colitis. <b>2021</b> , 5, 419-425	

347	The Management of the Hospitalized Ulcerative Colitis Patient, the Medical-Surgical Conundrum. <b>2021</b> , 23, 25	
346	The Role of Mitochondria Dysfunction in Inflammatory Bowel Diseases and Colorectal Cancer. <b>2021</b> , 22,	1
345	Colorectal Cancer in Inflammatory Bowel Disease: Mechanisms and Management. 2021,	16
344	Efficacy of a Preparation Based on Calcium Butyrate, , , and Fructooligosaccharides in the Prevention of Relapse in Ulcerative Colitis: A Prospective Observational Study. <b>2021</b> , 10,	O
343	Herpes simplex virus vasculitis, colitis and enteritis. 2021,	
342	Measuring Histologic Activity in Inflammatory Bowel Disease: Why and How. <b>2022</b> , 29, 37-47	O
341	Therapeutic drug monitoring with vedolizumab in inflammatory bowel disease. <b>2019</b> , 65, 280-290	1
340	INFLAMMATORY BOWEL DISEASE CARE IN BRAZIL: HOW IT IS PERFORMED, OBSTACLES AND DEMANDS FROM THE PHYSICIANS' PERSPECTIVE. <b>2020</b> , 57, 416-427	3
339	[Inflammatory Bowel Disease and Vitamin D]. <b>2020</b> , 76, 275-281	О
338	Change in paradigm: impact of an IBD medical home on the outpatient management of acute severe ulcerative colitis. <b>2019</b> , 12,	
337	ERKRANKUNGEN DER VERDAUUNGSORGANE. <b>2020</b> , pA-1-pA7.8-14	
336	Extraintestinale Manifestationen und assoziierte Erkrankungen. <b>2020</b> , 453-465	
335	Platelets can reflect the severity of Crohn's disease without the effect of anemia. 2020, 75, e1596	2
334	Klinik der Colitis ulcerosa und Pouchitis. <b>2020</b> , 87-94	
333	Ulcerative colitis. <b>2020</b> , 2937-2950	О
332	Leiomyosarcoma and ulcerative colitis: Case report. <b>2020</b> , 35, 123-126	
331	GBcel Kŧavuz Berileriyle °nflamatuar Barsak Hastalŧklarāda Semptomlar ve Semptom YBetimi.	
330	Colitis inflamatorias: enfermedad inflamatoria intestinal, colitis microscpica y colitis isqumica. <b>2020</b> , 13, 419-426	1

329	STUDY OF VASCULAR ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. <b>2021</b> , 81-89	
328	Advanced Colonoscopy Techniques in Inflammatory Bowel Diseases. <b>2022</b> , 485-507	
327	Disseminated Colitic Cancer Identified in Two Patients who had Undergone Surveillance Colonoscopies: A Case Report. <b>2020</b> , 3, 151-159	
326	The Clinical Significance and Risk Factors of Colorectal Stricture in Ulcerative Colitis. <b>2020</b> , 14, 535-536	
325	Gull para el manejo de colitis ulcerativa en poblacifi adulta (actualizacifi). <b>2020</b> , 35, 2-62	O
324	Biologics for the Management of Inflammatory Bowel Disease: A Review in Tuberculosis-Endemic Countries. <b>2020</b> , 14, 685-698	2
323	Finger clubbing in inflammatory bowel disease: association with upper small bowel lesions and need of surgery in Crohn's disease. <b>2021</b> , 33, 844-851	
322	When Not to Pouch: Important Considerations for Patient Selection for Ileal Pouch-Anal Anastomosis. <b>2017</b> , 13, 466-475	8
321	Short-Term and Long-Term Outcomes of Infliximab and Tacrolimus Treatment for Moderate to Severe Ulcerative Colitis: Retrospective Observational Study. <b>2018</b> , 64, E140-E148	5
320	[Effects of circular RNA circ-SOD2 on intestinal epithelial barrier and ulcerative colitis]. <b>2019</b> , 51, 805-812	1
319	Correlation of Hypoxia-inducible facto-1\(\textit{h}\)nd C-reactive protein with disease evaluation in patients with ulcerative colitis. <b>2020</b> , 12, 7826-7835	1
318	Probiotics: current regulatory aspects of probiotics for use in different disease conditions. <b>2022</b> , 465-499	
317	Diversion proctocolitis and the problem of the forgotten rectum in inflammatory bowel diseases: A systematic review. <b>2021</b> , 9, 1157	1
316	Histopathological Evaluation of the Effect of Eugenol in a Model of Trinitrobenzenesulfonic Acid-Induced Colitis in Rats. <b>2021</b> , 48, 9-14	
315	IBD Diagnosis and Evaluation. <b>2022</b> , 751-764	
314	Long-Term Outcomes and Predictive Factors of Hospitalized Patients with Severe Ulcerative Colitis Treated with Intravenous Corticosteroids. <b>2021</b> , 10,	O
313	Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry. <b>2021</b> ,	0
312	Consenso latinoamericano acerca de indicadores de calidad para Clflicas de Atencifi Integral para pacientes con enfermedad inflamatoria intestinal: PANCCO-GETECCU. <b>2021</b> ,	

311	Pediatric Ulcerative Colitis Is A Fibrotic Disease And Linked With Chronicity Of Inflammation.  Journal of Crohn and Colitis, 2021,	O
310	Colorectal Dysplasia and Cancer Surveillance in Ulcerative Colitis. <b>2021</b> , 9,	1
309	Clinical Features and Outcomes of Primary Sclerosing Cholangitis in the Highly Admixed Brazilian Population. <b>2021</b> , 2021, 7746401	О
308	Fecal microbiota profiling in irritable bowel syndrome and inflammatory bowel disease patients with irritable bowel syndrome-type symptoms. <b>2021</b> , 21, 433	O
307	Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium. <b>2021</b> ,	2
306	Gastrointestinal Disorders. <b>2022</b> , 449-460	
305	Bringing to Light the Risk of Colorectal Cancer in Inflammatory Bowel Disease: Mucosal Glycosylation as a Key Player. <b>2021</b> ,	O
304	Liver involvement in inflammatory bowel disease: What should the clinician know?. <b>2021</b> , 13, 1534-1551	O
303	Microscopic colitis and the role of the specialist inflammatory bowel disease nurse: a clinical review. <b>2021</b> , 19, 20-26	
302	Latin American consensus on the quality indicators for comprehensive care clinics for patients with inflammatory bowel disease: PANCCO-GETECCU. <b>2021</b> , 87, 89-89	1
301	Recent Advance in the Management of Dysplasia in the Ulcerative Colitis. 2021, 9, 50-56	
300	Integrin-dependent adhesion of T cells to MAdCAM-1 is blocked by vedolizumab in patients with chronic refractory pouchitis. <b>2021</b> , 14, 17562848211054707	
299	Chinese consensus on prevention of colorectal neoplasia (2021, Shanghai) 2022,	O
298	Differential-diagnostic criteria of active ulcerative colitis and irritable bowel syndrome. <b>2021</b> , 90, 33-43	
297	Colitis due to Cytomegalovirus and Herpes Simplex Type 2 as a Complication of a First Presentation of Inflammatory Bowel Disease <b>2022</b> , 29, 56-60	
296	Time to Flexible Sigmoidoscopy or Colonoscopy in Patients Admitted With Ulcerative Colitis Has Decreased From 2012 to 2018. <b>2021</b> , 3,	
295	Safety and tolerability of a single infusion of autologous ex vivo expanded regulatory T cells in adults with ulcerative colitis (ER-TREG 01): protocol of a phase 1, open-label, fast-track dose-escalation clinical trial. <b>2021</b> , 11, e049208	3
294	The Risk of Opportunistic Infections in Patients with Inflammatory Bowel Disease. 2022, 01,	

293	Risk of malignancy in patients with inflammatory bowel disease: a population-based cohort study from China <b>2022</b> ,		Ο
292	Artificial Endoscopy and Inflammatory Bowel Disease: Welcome to the Future 2022, 11,		1
291	Advanced endoscopy for the management of inflammatory digestive diseases: a review of the JGES core session <b>2022</b> ,		1
290	High Degree of Practice Variability in Colonic Dysplasia Surveillance for Patients With Inflammatory Bowel Disease <b>2022</b> ,		
289	Effect of disease duration on the association between C-reactive protein-albumin ratio and endoscopic activity in ulcerative colitis <b>2022</b> , 22, 39		1
288	Letter to the Editor Journal of Crohn\s and Colitis, 2022,	1.5	
287	Histomorphological Diagnosis of Ulcerative Colitis and Associated Conditions.		0
286	Patients with inflammatory bowel disease and post-inflammatory polyps have an increased risk of colorectal neoplasia: A meta-analysis <b>2022</b> , 10, 966-984		
285	Current status of cytomegalovirus colitis among patients with inflammatory bowel disease in China: A questionnaire-based multi-center study <b>2022</b> ,		0
284	Incident Colorectal Cancer in Inflammatory Bowel Disease <b>2022</b> , 14,		O
283	Integrated bioinformatics and network pharmacology to identify the therapeutic target and molecular mechanisms of Huangqin decoction on ulcerative Colitis <b>2022</b> , 12, 159		6
282	Efficacy and safety of tofacitinib in the treatment of ulcerative colitis: real-life experience in Andalusia <b>2022</b> ,		O
281	SPP1 in infliximab resistant ulcerative colitis and associated colorectal cancer: an analysis of differentially expressed genes <b>2022</b> ,		О
280	ECCO Position on harmonization of Crohn's disease mucosal histopathology <i>Journal of Crohn</i> and <i>Colitis</i> , <b>2022</b> ,	1.5	Ο
279	Vitamin D in Inflammatory Bowel Diseases. Mechanisms of Action and Therapeutic Implications <b>2022</b> , 14,		6
278	Cross-Sectional Imaging Instead of Colonoscopy in Inflammatory Bowel Diseases: Lights and Shadows <b>2022</b> , 11,		O
277	Incidence and Risk Factors of Cancer in the Anal Transitional Zone and Ileal Pouch following Surgery for Ulcerative Colitis and Familial Adenomatous Polyposis <b>2022</b> , 14,		1
276	Colorectal cancer screening and surveillance in patients with inflammatory bowel disease in 2021 <b>2022</b> , 28, 502-516		2

275	Efficacy and safety of adjuvant curcumin therapy in ulcerative colitis: A systematic review and meta-analysis <b>2022</b> , 115041	1
274	Markers of systemic inflammation in acute attacks of ulcerative colitis: What level of C-reactive protein constitutes severe colitis?. <i>Journal of Crohn</i> and Colitis, <b>2022</b> ,	2
273	Mucosal Gene Transcript Signatures in Treatment NaWe Inflammatory Bowel Disease: A Comparative Analysis of Disease to Symptomatic and Healthy Controls in the European IBD-Character Cohort <b>2022</b> , 15, 5-25	0
272	Endoscopic colorectal cancer surveillance in inflammatory bowel disease: Considerations that we must not forget <b>2022</b> , 14, 85-95	O
271	Contr <b>l</b> es qualit <b>'</b> et rglementation des probiotiques, pourquoi une volution est ncessaire et indispensable. <b>2018</b> , N° 1, 41-42	
270	Chronisch-entzfidliche Darmerkrankungen: Morbus Crohn und Colitis ulcerosa. <b>2022</b> , 237-256	
269	Prevalence of antinuclear antibodies in inflammatory bowel disease and seroconversion after biological therapy <b>2022</b> , 15, 17562848221077837	
268	Aloe vera gel attenuates acetic acid-induced ulcerative colitis in adult male Wistar rats <b>2022</b> , 9, 640-646	2
267	Therapeutic approaches of immunogenetic molecules in inflammatory bowel disease management. <b>2022</b> , 377-389	
266	Ileal and colonic Crohn's disease: Does location makes a difference in therapy efficacy?. <b>2022</b> , 3, 100097	1
265	Absence of Oral Opportunistic Infections in Patients with Inflammatory Bowel Disease Receiving Anti-TNF-Band Anti-Integrin-ETherapy <b>2022</b> , 10,	
264	Adherence to endoscopic surveillance for advanced lesions and colorectal cancer in inflammatory bowel disease: an AEG and GETECCU collaborative cohort study <b>2022</b> ,	Ο
263	Case Report: Proteinase 3 Antineutrophil Cytoplasmic Antibody-Associated Ulcerative Colitis Presenting as Recurrent Intestinal Pseudo-Obstruction in a Teenage Patient With Proteinase 3 Immunohistochemical Staining <b>2022</b> , 10, 822491	1
262	Systematic review and meta-analysis: incidence and factors for progression to advanced neoplasia in inflammatory bowel disease patients with indefinite and low-grade dysplasia <b>2022</b> ,	
261	Endoscopic mucosal biopsy [þathology and biomarker testing. <b>2022</b> , 2846-2928	
260	FEATURES OF THE CLINIC AND DIAGNOSIS OF CROHN'S DISEASE IN CHILDREN AT THE PRESENT STAGE. <b>2022</b> ,	
259	Indications and Surgical Technique for Transanal Proctectomy and Ileal Pouch-Anal Anastomosis for Inflammatory Bowel Disease <b>2022</b> , 35, 135-140	
258	Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis <b>2022</b> , 9,	Ο

257	Systematic review and meta-analysis: the advantage of endoscopic Mayo score 0 over 1 in patients with ulcerative colitis <b>2022</b> , 22, 92	О
256	Inflammatory bowel disease-related colorectal cancer: Past, present and future perspectives <b>2022</b> , 14, 547-567	3
255	Emerging IBD demographics, phenotype and treatment in South Asia, South-East Asia and Middle East: Preliminary findings from the IBD-Emerging Nations' Consortium <b>2022</b> ,	2
254	Impact of direct-access IBD physician delivered endoscopy on clinical outcomes: a pre-implementation and post-implementation study. flgastro-2021-102047	O
253	Development and Validation of a Deep Neural Network for Accurate Identification of Endoscopic Images From Patients With Ulcerative Colitis and Crohn's Disease <b>2022</b> , 9, 854677	1
252	Characteristics and Outcomes of Left-sided Ulcerative Colitis With a Cecal/Periappendiceal Patch of Inflammation <b>2022</b> ,	O
251	Endoscopic Surveillance in Inflammatory Bowel Diseases: Selecting a Suitable Technology <b>2022</b> , 9, 855652	1
250	Impact of the SARS-CoV-2 Delta Variant on the Psychological States and Health-Related Quality of Life in Patients With Crohn's Disease <b>2022</b> , 9, 795889	O
249	Stringent screening strategy significantly reduces reactivation rates of tuberculosis in patients with inflammatory bowel disease on anti-TNF therapy in tuberculosis endemic region <b>2022</b> ,	1
248	A United States expert consensus to standardise definitions, follow-up, and treatment targets for extra-intestinal manifestations in inflammatory bowel disease <b>2022</b> ,	1
247	Measurement of Serum IgG Anti-Integrin	О
246	Artificial Intelligence Program to Predict p53 Mutations in Ulcerative Colitis-Associated Cancer or Dysplasia <b>2022</b> ,	1
245	Sphk2 deletion is involved in structural abnormalities and Th17 response but does not aggravate colon inflammation induced by sub-chronic stress <b>2022</b> , 12, 4073	
244	Combining biological therapies in patients with inflammatory bowel disease: a Finnish multi-centre study <b>2022,</b> 1-6	1
243	Taxifolin Alleviates DSS-Induced Ulcerative Colitis by Acting on Gut Microbiome to Produce Butyric Acid <b>2022</b> , 14,	2
242	Risk of Cancer in Inflammatory Bowel Disease and Pitfalls in Oncologic Therapy <b>2022</b> , 1	O
241	Immune Thrombocytopenic Purpura as an Extraintestinal Manifestation in a Patient with Ulcerative Colitis <b>2022</b> , 16, 140-147	1
<b>2</b> 40	Efficacy of induction therapy with calcineurin inhibitors in combination with ustekinumab for acute severe ulcerative colitis <b>2022</b> ,	1

239	Association Between Ex Vivo Human Ulcerative Colitis Explant Protein Secretion Profiles and Disease Behaviour <b>2022</b> , 1		
238	Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn's disease in patients with prior failure of anti-tumour necrosis factor treatment <b>2022</b> , 22, 143		2
237	Paediatric Crohn Disease Patients Have Increased Inflammatory Markers Compared to Adult Patients prior to Biological Treatment. <b>2022</b> , 2022, 1-11		
236	Intestinal Wnt in the transition from physiology to oncology 2022, 13, 168-185		
235	Influence of comorbidities on treatment considerations for first-line biologic prescribing in patients with inflammatory bowel disease in the UK. flgastro-2021-101995		
234	A specific calprotectin neo-epitope (CPa9-HNE) in serum from inflammatory bowel disease patients is associated with neutrophil activity and endoscopic severity <i>Journal of Crohn</i> and Colitis, <b>2022</b> ,	1.5	1
233	Chinese herbal medicines in the treatment of ulcerative colitis: a review 2022, 17, 43		1
232	A REVIEW ON PHARMACOLOGICAL AND THERAPEUTIC INSIGHT OF OZANIMOD FOR COLON DISEASE IN NANO-STRUCTURE. 13-19		
231	Magnifying endoscopy is useful for tumor border diagnosis in ulcerative colitis patients 2022,		1
230	Tacrolimus (FK506) for induction of remission in corticosteroid-refractory ulcerative colitis <b>2022</b> , 4, CD007216		O
229	Development of a Convolutional Neural Network-Based Colonoscopy Image Assessment Model for Differentiating Crohn's Disease and Ulcerative Colitis <b>2022</b> , 9, 789862		
228	Interleukin-26 Expression in Inflammatory Bowel Disease and Its Immunoregulatory Effects on Macrophages <b>2022</b> , 9, 797135		O
227	Serum oncostatin M predicts mucosal healing in patients with inflammatory bowel diseases treated with anti-TNF, but not vedolizumab <b>2022</b> ,		О
226	Changes in Salivary Parameters of Oral Immunity after Biologic Therapy for Inflammatory Bowel Disease <b>2021</b> , 11,		1
225	The role of cytomegalovirus colitis on short- and long-term outcomes for patients with ulcerative colitis <b>2021</b> , 1-8		0
224	Body Composition Changes and Related Factors in Patients with Ulcerative Colitis: A Retrospective Single-Center Study in China <b>2022</b> , 28, e933942		
223	Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease 2021, 11,		1
222	Artificial Neural Network Analysis-Based Immune-Related Signatures of Primary Non-Response to Infliximab in Patients With Ulcerative Colitis <b>2021</b> , 12, 742080		Ο

221	Danish Society for Gastroenterology and Hepatology's clinical recommendations for colonoscopic surveillance for colorectal dysplasia and cancer in patients with inflammatory bowel disease <b>2021</b> , 1-8	
220	Polypharmacy in Patients With Inflammatory Bowel Disease: Prevalence and Outcomes in a Single-center Series. <b>2021</b> , 56,	1
219	The psychological impact of inflammatory bowel disease as regards anxiety and depression: a single-center study. <b>2021</b> , 28,	2
218	Anti-Inflammatory, Antioxidant, and Healing-Promoting Effects of Extract in the Experimental Colitis in Rats <b>2021</b> , 2021, 9945244	3
217	Care of Women with Chronic Inflammatory Bowel Disease (Chronic IBD) During Pregnancy: Recommendations of the Obstetrics and Prenatal Medicine Working Group of the DGGG <b>2021</b> , 81, 1348-1353	3 <sup>1</sup>
216	Predictive value of fibrinogen in identifying inflammatory bowel disease in active stage <b>2021</b> , 21, 472	1
215	Mucosal gene expression profile of stricturing Crohn's disease: A preliminary study <b>2022</b> , 23, 149	
214	Revisiting fibrosis in inflammatory bowel disease: the gut thickens. <b>2021</b> ,	3
213	The LUCID study: living with ulcerative colitis; identifying the socioeconomic burden in Europe. <b>2021</b> , 21, 456	2
212	Editorial: shedding new light on extraintestinal manifestations in inflammatory bowel disease-authors' reply <b>2022</b> , 55, 1208-1209	
211	Microbial changes in stool, saliva, serum, and urine before and after anti-TNF-Etherapy in patients with inflammatory bowel diseases <b>2022</b> , 12, 6359	2
210	Differentially deregulated microRNAs as novel biomarkers for neoplastic progression in ulcerative colitis <b>2022</b> ,	O
209	Use of advanced endoscopic technology for optical characterization of neoplasia in patients with ulcerative colitis: a systematic review <b>2022</b> ,	0
208	Composite Sophora Colon-Soluble Capsule Ameliorates DSS-Induced Ulcerative Colitis in Mice via Gut Microbiota-Derived Butyric Acid and NCR ILC3 <b>2022</b> ,	
207	An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis <b>2022</b> , 11,	0
206	table1.xlsx. <b>2020</b> ,	
205	table2.xlsx. <b>2020</b> ,	
204	table3.xlsx. <b>2020</b> ,	

203 table4.xlsx. **2020**,

202	OUP accepted manuscript.		
201	C-reactive protein levels and prevalence of leukopenia in patients with inflammatory bowel disease treated with azathioprine and/or mesalazine: a real-life study <b>2022</b> , 20, eAO6500		О
200	Clinical aspects and prognosis of patients with inflammatory bowel disease associated with autoimmune liver diseases. <b>2022</b> , 45, 83-90		
199	Risk factors for underestimation of patient pain in outpatient colonoscopy 2022, 1-11		
198	Multicriteria Decision Analysis for Updating of Quality Indicators for Inflammatory Bowel Disease Comprehensive Care Units in Spain <i>Journal of Crohn</i> and Colitis, <b>2022</b> ,	1.5	O
197	An overview of ozanimod as a therapeutic option for adults with moderate-to-severe active ulcerative colitis <b>2022</b> ,		О
196	Minimal risk of lymphoma and non-melanoma skin cancer despite long-term use of thiopurines in patients with inflammatory bowel disease: A longitudinal cohort analysis from Northern India 2022,		2
195	Heterogeneity in pharmacological treatment and outcomes in Crohn's disease patients in Catalonia: a population-based observational study <b>2022</b> , 54, 1255-1264		
194	Diet Quality and Dietary Inflammatory Index in Dutch Inflammatory Bowel Disease and Irritable Bowel Syndrome Patients <b>2022</b> , 14,		2
193	OPPORTUNISTIC SCREENING FOR COLORECTAL CANCER IN HIGH-RISK PATIENTS IN FAMILY MEDICINE PRACTICES IN THE REPUBLIC OF CROATIA <b>2021</b> , 60, 17-26		
192	The Role of Magnetic Resonance Enterography in Crohn Disease: A Review of Recent Literature. <b>2022</b> , 12, 1236		O
191	Clinical and sonographic parallels of gastroesophageal reflux disease and comorbid gastrointestinal pathology. <b>2022</b> , 36-43		
190	Leucine-Rich Alpha-2 Glycoprotein in Monitoring Disease Activity and Intestinal Stenosis in Inflammatory Bowel Disease. <b>2022</b> ,		O
189	Venlafaxine as an Adjuvant Therapy for Inflammatory Bowel Disease Patients With Anxious and Depressive Symptoms: A Randomized Controlled Trial. <b>2022</b> , 13,		О
188	Epstein <b>B</b> arr Virus and Human Cytomegalovirus Infection in Intestinal Mucosa of Chinese Patients With Inflammatory Bowel Disease. <b>2022</b> , 13,		O
187	Management of patients with Intestinal Bowel Disease and COVID-19: A review of current evidence and future perspectives. <b>2022</b> , 45, 383-389		
186	Comparative Efficacy of Biologic Therapies for Inducing Response and Remission in Fistulizing Crohn Disease: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.		1

185	Influencia del tratamiento biolgico en los factores de riesgo cardiovascular de los pacientes con enfermedad inflamatoria intestinal. <b>2022</b> ,		
184	Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis.		1
183	Mucosa-Colonizing Microbiota Correlate With Host Autophagy Signaling in Patients With Inflammatory Bowel Disease. <b>2022</b> , 13,		O
182	Gut Microbiota and Metabolite Changes in Patients With Ulcerative Colitis and Clostridioides difficile Infection. <b>2022</b> , 13,		Ο
181	Mediterranean diet diminishes the effects of Crohn's disease and improves its parameters: A systematic review. 026010602211022		
180	The Effect of Empowering Education Combined With Mindfulness Meditation Training on Negative Emotion and Quality of Life in Patients With Inflammatory Bowel Disease. <b>2022</b> , 16,		
179	Lymphocyte-to-monocyte ratio is a short-term predictive marker of ulcerative colitis after induction of advanced therapy. <b>2022</b> , 10,		
178	Early intestinal ultrasound predicts intravenous corticosteroid response in hospitalized patients with severe ulcerative colitis. <i>Journal of Crohn</i> and Colitis,	1.5	Ο
177	Serum Levels of Infliximab Biosimilar in a Child Delivered From a Mother Treated for Ulcerative Colitis.		
176	EASL Clinical Practice Guidelines on sclerosing cholangitis. <b>2022</b> ,		4
175	Chemoprevention of Colitis-Associated Dysplasia or Cancer in Inflammatory Bowel Disease. 2022,		2
174	Nutrition and Supplementation in Ulcerative Colitis. <b>2022</b> , 14, 2469		1
173	Routine Histology Based Diagnosis of CMV Colitis was Rare in Pediatric Patients. Publish Ahead of Print,		
172	Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. 9,		O
171	Colitis ulcerosa laparoszkpos sebszi kezelse, rūid s hosszītūleredmhyek a szegedi Sebszeti Klinikfi. <b>2022</b> , 75, 161-168		
170	Liver Transplant and Active Ulcerative Colitis: A Case Report. <b>2022</b> ,		O
169	Can dysplasia surveillance be better targeted in ulcerative colitis by using faecal calprotectin?. 1-8		
168	A Retrospective Analysis of Clinical Features and Treatment of the Inflammatory Bowel Disease in China. Volume 15, 3587-3597		Ο

167	Oral beclomethasone dipropionate as an add-on therapy and response prediction in Korean patients with ulcerative colitis.		
166	State-of-the-art surgery for Crohn disease: Part II dolonic Crohn disease and associated neoplasms.		Ο
165	Rare Mucocutaneous Manifestations of Ulcerative Colitis: A Case report of Pyostomatitis Vegetans and Sweet's Syndrome. <b>2022</b> ,		0
164	Memory T Cell Subpopulations as Early Predictors of Remission to Vedolizumab in Ulcerative Colitis. 9,		
163	SARS-CoV-2-inactivated vaccine hesitancy and the safety in inflammatory bowel disease patients: a single-center study. <b>2022</b> , 15, 175628482211017		
162	Presence of Phlebitis in Aseptic Nasal Septal Abscess Complicated with Ulcerative Colitis; Possible Association with Granulomatosis with Polyangiitis: A Case Report. <b>2022</b> ,		O
161	Molecular characterization and antibiotic resistance of Clostridioides difficile in patients with inflammatory bowel disease from two hospitals in China. <b>2022</b> ,		0
160	Measuring Mood and Anxiety Disorders by Patient Reported Outcomes in Inflammatory Bowel Disease: A Literature Review Update <b>2022</b> , 17,		1
159	Ileal PouchAnal Anastomosis and Pouchitis: The Role of the Microbiota in the Pathogenesis and Therapy. <b>2022</b> , 14, 2610		
158	The impact of COVID-19 on patients with IBD in a prospective European cohort study. <i>Journal of Crohn</i> and Colitis,	1.5	0
157	Intestinal Ultrasonography as a Tool for Monitoring Disease Activity in Patients with Ulcerative Colitis. <b>2022</b> , 2022, 1-6		0
156	Visualization of Inflammation in Experimental Colitis by Magnetic Resonance Imaging Using Very Small Superparamagnetic Iron Oxide Particles. 13,		0
155	Management of pouch neoplasia: consensus guidelines from the International Ileal Pouch Consortium. <b>2022</b> ,		1
154	Hypo-osmotic stress induces the epithelial alarmin IL-33 in the colonic barrier of ulcerative colitis. <b>2022</b> , 12,		
153	Comparative Acceptability of Therapeutic Maintenance Regimens in Patients With Inflammatory Bowel Disease: Results From the Nationwide ACCEPT2 Study.		0
× =0			
152	Diagnostic Delay in Paediatric Inflammatory Bowel Disease A Systematic Investigation. 2022, 11, 4161		
152	Diagnostic Delay in Paediatric Inflammatory Bowel Disease A Systematic Investigation. 2022, 11, 4161  Management of immune checkpoint inhibitor in patients with cancer and pre-existing inflammatory bowel disease: Recommendations from the GETAID. 2022,		2
	Management of immune checkpoint inhibitor in patients with cancer and pre-existing inflammatory		2

149	Relapse rates after withdrawal of thiopurines in patients with inflammatory bowel disease.	1
148	Self-management interventions to support help-seeking behaviours in inflammatory bowel disease: a scoping review. <b>2022</b> , 20, 30-41	
147	Impact of Endoscopic and Histologic Activity on Disease Relapse in Ulcerative Colitis. <b>2022</b> , Publish Ahead of Print,	
146	Chemistry of Hydrogen Peroxide Formation and Elimination in Mammalian Cells, and Its Role in Various Pathologies. <b>2022</b> , 2, 256-274	5
145	Image-Enhanced Endoscopy Surveillance of Colon and Pouch Dysplasia in IBD. Publish Ahead of Print,	
144	Performance measures for colonoscopy in inflammatory bowel disease patients: European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative. <b>2022</b> , 54, 904-915	O
143	Safety and tolerability of spesolimab in patients with ulcerative colitis. 1-11	О
142	Spondyloarthropathy in Inflammatory Bowel Disease: From Pathophysiology to Pharmacological Targets. <b>2022</b> , 82, 1151-1163	
141	An updated systematic review and meta-analysis of fecal microbiota transplantation for the treatment of ulcerative colitis. <b>2022</b> , 101, e29790	
140	Emergency colectomy for acute severe ulcerative colitis: a nationwide survey on technical strategies of the Italian society of colorectal surgery (SICCR).	O
140		
	strategies of the Italian society of colorectal surgery (SICCR).	
139	strategies of the Italian society of colorectal surgery (SICCR).  Colorectal Cancer in Ulcerative Colitis: Mechanisms, Surveillance and Chemoprevention. 2022, 29, 6091-6114  Pancolonic Dye Spray Chromoendoscopy to Detect and Resect Ill-Defined Neoplastic Lesions in	
139	strategies of the Italian society of colorectal surgery (SICCR).  Colorectal Cancer in Ulcerative Colitis: Mechanisms, Surveillance and Chemoprevention. 2022, 29, 6091-6114  Pancolonic Dye Spray Chromoendoscopy to Detect and Resect Ill-Defined Neoplastic Lesions in Colonic Inflammatory Bowel Disease.	
139 138 137	Strategies of the Italian society of colorectal surgery (SICCR).  Colorectal Cancer in Ulcerative Colitis: Mechanisms, Surveillance and Chemoprevention. 2022, 29, 6091-6114  Pancolonic Dye Spray Chromoendoscopy to Detect and Resect Ill-Defined Neoplastic Lesions in Colonic Inflammatory Bowel Disease.  Non-systemic Epstein-Barr virus infection in patients with ulcerative colitis.  To investigate the effects of artemisinin on inflammatory factors and intestinal microbiota in rats	
139 138 137	Colorectal Cancer in Ulcerative Colitis: Mechanisms, Surveillance and Chemoprevention. 2022, 29, 6091-6114  Pancolonic Dye Spray Chromoendoscopy to Detect and Resect Ill-Defined Neoplastic Lesions in Colonic Inflammatory Bowel Disease.  Non-systemic Epstein-Barr virus infection in patients with ulcerative colitis.  To investigate the effects of artemisinin on inflammatory factors and intestinal microbiota in rats with ulcerative colitis based on network pharmacology. 1,  The Feasibility, Safety, and Long-term Outcomes of Endoscopic Submucosal Dissection for	
139 138 137 136	Colorectal Cancer in Ulcerative Colitis: Mechanisms, Surveillance and Chemoprevention. 2022, 29, 6091-6114  Pancolonic Dye Spray Chromoendoscopy to Detect and Resect Ill-Defined Neoplastic Lesions in Colonic Inflammatory Bowel Disease.  Non-systemic Epstein-Barr virus infection in patients with ulcerative colitis.  To investigate the effects of artemisinin on inflammatory factors and intestinal microbiota in rats with ulcerative colitis based on network pharmacology. 1,  The Feasibility, Safety, and Long-term Outcomes of Endoscopic Submucosal Dissection for Colorectal Neoplasia in Patients With Inflammatory Bowel Disease. Publish Ahead of Print,  Lymphocyte to monocyte ratio and serum albumin changes predict tacrolimus therapy outcomes in	

131	Fecal microbiota transplantation versus glucocorticoids for the induction of remission in mild to moderate ulcerative colitis. <b>2022</b> , 20,	1
130	Translation into Spanish and validation of a short questionnaire to measure the control of inflammatory bowel disease from the patient's perspective: IBD-Control, EII-Control. <b>2022</b> , 45, 524-534	
129	Clinical procedures used to diagnose inflammatory bowel disease: real-world evidence from a Danish nationwide population-based study. <b>2022</b> , 9, e000958	
128	Atypical Forms of Pyoderma Gangrenosum in Inflammatory Bowel Disease: Report of Four Cases and Literature Review. Volume 15, 449-456	O
127	Colorectal cancer risk of flat low-grade dysplasia in inflammatory bowel disease: a systematic review and proportion meta-analysis.	1
126	Perimyokarditis als Komplikation einer medikamentßen Mehrfachtherapie bei Colitis ulcerosa. <b>2022</b> , 147, 1055-1060	O
125	Intestinal ultrasound is accurate to determine endoscopic response and remission in patients with moderate to severe ulcerative colitis: a longitudinal prospective cohort study. <b>2022</b> ,	O
124	Clinical Case of Tofacitinib Therapy in Autoimmune Alopecia in Patient with Ulcerative Colitis.	O
123	MPST deficiency promotes intestinal epithelial cell apoptosis and aggravates inflammatory bowel disease via AKT. <b>2022</b> , 56, 102469	3
122	The role of diet in genotoxicity of fecal water derived from IBD patients and healthy controls. <b>2022</b> , 168, 113393	O
121	FOXP3 variants are independently associated with transforming growth factor <b>1</b> plasma levels in female patients with inflammatory bowel disease. <b>2022</b> , 77, 100084	О
120	Viszeralchirurgie. <b>2022</b> , 223-437	O
119	Colorectal Cancer in Childhood-onset Inflammatory Bowel Disease: A Scandinavian Register-based Cohort Study, 1969 <b>1</b> 017. <b>2022</b> , 75, 480-484	1
118	Colorectal Cancer in Inflammatory Bowel Diseases: Epidemiology and Prevention: A Review. <b>2022</b> , 14, 4254	1
117	Ulcerative colitis-associated bronchiectasis: A rare extraintestinal manifestation of inflammatory bowel disease: A case report. <b>2022</b> , 101, e30202	O
116	Serum and Mucosal CD30 in Pediatric Inflammatory Bowel Diseases: Useful Biomarker for Diagnosis and Disease Activity Monitoring?.	O
115	Analysis of clinical characteristics of mesalazine-induced cardiotoxicity. 13,	1
114	Predicting In-Hospital Mortality in Severe COVID-19: A Systematic Review and External Validation of Clinical Prediction Rules. <b>2022</b> , 10, 2414	O

113	Crypt-top and crypt-bottom colonic epithelial cell microRNA profiling reveals cell type-specific response in active and quiescent ulcerative colitis.	O
112	Sistemik immß-inflamasyon indeksinin ßeratif kolitteki ßemi. 521-528	O
111	Mucosal Interleukin-10 depletion in steroid-refractory Crohn's disease patients. <b>2022</b> , 10,	Ο
110	Screening for spondyloarthritis in patients with inflammatory bowel diseases.	1
109	Effect of disease duration on fecal biomarkers in ulcerative colitis: a prospective cohort study. <b>2022</b> , 22,	O
108	High incidence of surgery and initiation of medical therapies after colectomy for ulcerative colitis or inflammatory bowel disease unclassified. <b>2022</b> ,	O
107	Effect of closed and permanent stoma on disease course, psychological well-being and working capacity in Swiss IBD cohort study patients. <b>2022</b> , 17, e0274665	0
106	Thromboembolism is associated with poor prognosis and high mortality in patients with inflammatory bowel disease: A´casedontrol study.	O
105	An extremes of phenotype approach confirms significant genetic heterogeneity in patients with ulcerative colitis.	0
104	Impact of Clostridioides difficile infection in patients admitted with ulcerative colitis. 1-8	O
103	Histopathological assessment of the microscopic activity in inflammatory bowel diseases: What are we looking for?. 28, 5300-5312	0
102	Future of Endoscopy in Inflammatory Bowel Diseases (IBDs). 2022,	Ο
101	Image-Enhanced Endoscopy in the Surveillance of Colitis-Associated Neoplasia. <b>2022</b> , 32, 845-862	0
100	Endoscopic resection is feasible for high-grade dysplasia in patients with ulcerative colitis. 1-6	Ο
99	Risk factors for colorectal cancer in IBD patients. <b>2022</b> , 140-146	0
98	Endoscopic Management of Colitis-Associated Neoplasia. <b>2022</b> , 32, 863-873	O
97	Clinical features and oncological outcomes of intestinal cancers associated with ulcerative colitis and Crohn disease.	О
96	Validity of Inflammatory Bowel Disease Diagnoses in the Danish National Patient Registry: A Population-Based Study from the North Denmark Region. Volume 14, 1099-1109	Ο

95	Diagnosis and Classification of Inflammatory Bowel Disease Strictures. <b>2022</b> , 32, 615-629	О
94	Development and Course of Inflammatory Bowel Disease-Associated Intestinal Cancer. <b>2022</b> , 23-31	O
93	Inflammatory Biomarkers of Extracellular Matrix Remodeling and Disease Activity in Crohn Disease and Ulcerative Colitis. <b>2022</b> , 11, 5907	0
92	Prophylaxis for Pneumocystis jirovecii pneumonia in patients with inflammatory bowel disease: A systematic review.	O
91	Questions to consider when caring for patients with ulcerative colitis.	0
90	Importance of eosinophilic infiltration of the colonic mucosa in ulcerative colitis patients who are refractory to maintenance therapy: A prospective, single-center study. <b>2022</b> , 101, e31017	O
89	Adsorptive cytapheresis for ulcerative colitis with focus on removing plateletets and platelet-aggregates.	0
88	Patient preferences and current practice for adults with steroid-resistant ulcerative colitis: POPSTER mixed-methods study. <b>2022</b> , 26, 1-118	O
87	Perspectivas actuales sobre la enfermedad inflamatoria intestinal pedi <b>l</b> irica con un enfoque en el manejo en el per <b>o</b> do de transici <b>o</b> . ¿Qu'debemos considerar?. <b>2022</b> ,	0
86	Steroid Resistance/Dependence Might Be an Alarming Feature for Cytomegalovirus Infection Among Ulcerative Colitis Patients With Increased Disease Activity. <b>2022</b> ,	O
85	Diagnosis and Monitoring of Ulcerative Colitis.	0
84	Innovative, complementary and alternative therapy in inflammatory bowel diseases: A broad 2020s update. 1,	O
83	Post-inflammatory polyps burden as a prognostic marker of disease-outcome in patients with inflammatory bowel disease.	0
82	Dysplastic crypts in asymmetric branching found in ulcerative colitis-associated dysplasia. <b>2022</b> , 240, 154178	O
81	Tackling the Inflammatory Burden of Psoriasis: A Multidisciplinary Approach. 27-35	О
80	Hidradenitis suppurativa and inflammatory bowel disease in a nested case-control study. 2022,	O
79	Akkermansia muciniphila alleviates colonic epithelial endoplasmic reticulum stress through activation of farnesoid X receptors in murine experimental colitis.	0
78	Salidroside alleviates ulcerative colitis via inhibiting macrophage pyroptosis and repairing the dysbacteriosis-associated Th17/Treg imbalance.	O

77	Comprehensive Phenotyping in Inflammatory Bowel Disease: Search for Biomarker Algorithms in the Transkingdom Interactions Context. <b>2022</b> , 10, 2190	О
76	Central venous sinus thrombosis in a young girl with ulcerative colitis. 2022, 15, e249904	O
75	Corticoides en la Enfermedad Inflamatoria Intestinal: ¿siguen siendo una opcifi terapùtica?. 2022,	0
74	Non-invasive monitoring and treat-to-target approach are cost-effective in patients with mildshoderate ulcerative colitis.	О
73	Long-term outcomes of patients with acute severe ulcerative colitis treated with cyclosporine rescue therapy. 1-6	O
72	Improvement of ulcerative colitis control by searching and restricting of inflammatory trigger factors in daily clinical practice.	O
71	Development of Annexin A1-surface-functionalized metal-complex multi-wall lipid core nanocapsules and effectiveness on experimental colitis. <b>2022</b> , 181, 49-59	0
70	Single-cell RNA-sequencing combined with bulk RNA-sequencing analysis of peripheral blood reveals the characteristics and key immune cell genes of ulcerative colitis. 10, 12116-12135	О
69	Impact of Bifidobacterium longum NSP001 on DSS-induced colitis in conventional and humanised mice. <b>2023</b> , 12, 1109-1118	0
68	Histologic healing and factors associated with complete remission following conventional treatment in ulcerative colitis. <b>2022</b> , 15, 175628482211406	О
67	Pretreating mesenchymal stem cells with IL-6 regulates the inflammatory response of DSS-induced ulcerative colitis in rats. <b>2023</b> , 76, 101765	О
66	A review of the therapeutic management of ulcerative colitis. <b>2022</b> , 15, 175628482211381	О
65	Therapeutic targets and pharmacological mechanisms of Coptidis Rhizoma against ulcerative colitis: Findings of system pharmacology and bioinformatics analysis. 13,	О
64	Stigmatization and resilience in inflammatory bowel disease patients at one-year follow-up. 1,	О
63	The role of biopsy protocol in inflammatory bowel disease: getting the diagnosis right first time.	0
62	The pregnancy outcome and drug usage during pregnancy among Taiwanese inflammatory bowel disease patients.	О
61	ECCO Guidelines on Inflammatory Bowel Disease and Malignancies.	3
60	Transabdominal ultrasound in the diagnosis and dynamic follow-up of a patient with nonspecific ulcerative colitis (case report). <b>2022</b> , 21, 92-99	О

59	Risks of colorectal cancer and biliary cancer according to accompanied primary sclerosing cholangitis in Korean patients with ulcerative colitis: a nationwide population-based study.	0
58	Clinical effect of mirikizumab treatment on bowel urgency in patients with moderately to severely active ulcerative colitis and the clinical relevance of bowel urgency improvement for disease remission.	O
57	Dietary adherence to the Mediterranean diet pattern in a randomized clinical trial of patients with quiescent ulcerative colitis. 9,	O
56	Quality of surveillance impacts the colitis-associated advanced neoplasia risk: a multicenter case-control study. <b>2022</b> ,	O
55	Labordiagnostik. <b>2023</b> , 79-86	0
54	Nutritional Status Indicators as a Predictor of Achieving Remission at Week 14 during Vedolizumab Therapy in Patients with Ulcerative Colitis: A Pilot Study. <b>2023</b> , 15, 240	O
53	Increased Proportion of Colorectal Cancer in Patients With Ulcerative Colitis Undergoing Surgery in the Netherlands. <b>2023</b> , Publish Ahead of Print,	O
52	The Usefulness of Tissue Calprotectin in Pediatric Crohn Disease A Pilot Study. 2023, 5, 28-36	O
51	Wumei Wan attenuates angiogenesis and inflammation by modulating RAGE signaling pathway in IBD: Network pharmacology analysis and experimental evidence. <b>2023</b> , 154658	0
50	RISK FACTORS FOR NEOPLASIA IN PATIENS WITH ULCERATIVE COLITIS. 2023, 1, 167	O
49	Effect of Biologics on the Risk of Advanced-Stage Inflammatory Bowel Disease-Associated Intestinal Cancer: A Nationwide Study. <b>2023</b> , Publish Ahead of Print,	O
48	In situ polyphenol-adhesive hydrogel enhanced the noncarcinogenic repairing of KGF on the gut epithelial barrier on TNBS-induced colitis rats. <b>2023</b> , 123323	O
47	Endoskopie. <b>2023</b> , 87-96	O
46	Managing ulcerative colitis after surgery. 9,	O
45	Diammonium glycyrrhizinate nanoliposomes impede tumor necrosis factor—pathway to affect oxidative stress response in rats with ulcerative colitis. <b>2022</b> , 12, 1196-1202	O
44	The Intake of Dicarbonyls and Advanced Glycation Endproducts as Part of the Habitual Diet Is Not Associated with Intestinal Inflammation in Inflammatory Bowel Disease and Irritable Bowel Syndrome Patients. <b>2023</b> , 15, 83	O
43	Licorice protects against ulcerative colitis via the Nrf2/PINK1-mediated mitochondrial autophagy. <b>2023</b> , 11,	О
42	Inflammatory Bowel Disease and Colorectal Cancer.	O

41	Inflammatory bowel disease and cognitive behavioral therapy (CBT) in the young. 2023, 237-247	О
40	Current trends and future perspectives of probiotics on human health: an overview. <b>2023</b> , 81-122	О
39	The genetics of non-monogenic IBD.	0
38	Risk of Cancer in Patients with Inflammatory Bowel Diseases and Keys for Patient Management. <b>2023</b> , 15, 871	О
37	Colitis-Associated Cancers. 2023, 773-788	0
36	Influence of biologic therapy on cardiovascular risk factors in patients with inflammatory bowel disease. <b>2023</b> , 46, 109-115	o
35	Time trend in surgical indications and outcomes in Ulcerative Colitis two decades in-depth retrospective analysis. <b>2023</b> ,	0
34	Probificos na terapia de manuten <b>o</b> em pacientes com retocolite ulcerativa: uma revis <b>o</b> integrativa. 80-94	O
33	NAMPT and NAPRT serum levels predict response to anti-TNF therapy in inflammatory bowel disease. 10,	0
32	Incremental Detection Rate of Dysplasia and Sessile Serrated Polyps/Adenomas Using Narrow-Band Imaging and Dye Spray Chromoendoscopy in Addition to High-Definition Endoscopy in Patients with Long-Standing Extensive Ulcerative Colitis: Segmental Tandem Endoscopic Study.	O
31	Vedolizumab is superior to infliximab in biologic natte patients with ulcerative colitis. <b>2023</b> , 13,	0
30	Impact of the body mass index on the retention of the anorectal mucosa after double-stapled ileal pouch-anal anastomosis for ulcerative colitis. <b>2023</b> , 23,	o
29	Neutrophil Membrane-Coated Mesoporous Silica Nanoparticles Loaded with Hydrocortisone Alleviate DSS-Induced Colitis in Mice. <b>2023</b> , 6, 2403-2412	0
28	The Role of Artificial Intelligence in Monitoring Inflammatory Bowel DiseaseThe Future Is Now. <b>2023</b> , 13, 735	0
27	Optimizaciñ del tratamiento de la colitis ulcerosa leve a moderada: Consenso Delphi CU-Forum. <b>2023</b> ,	0
26	The urotensin-II receptor: A marker for staging and steroid outcome prediction in ulcerative colitis.	o
25	Mucosal Genes Expression in Inflammatory Bowel Disease Patients: New Insights. 2023, 16, 324	0
24	Risk prediction model based on blood biomarkers for predicting moderate to severe endoscopic activity in patients with ulcerative colitis. 10,	О

23	Possible genetical predictors of efficacy and safety of budesonide-MMX in patients with mild-to-moderate ulcerative colitis, and safety comparison with methylprednisolone. 1-8	O
22	Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn disease: results from an Italian multicenter study. <b>2023</b> , 23, 293-304	O
21	Managing Risk of Dysplasia and Colorectal Cancer in Inflammatory Bowel Disease. 2023,	O
20	Clinical and Demographic Features and Treatment Approaches for Inflammatory Bowel Diseases (Crohn Disease, Ulcerative Colitis) in the Russia. The Primery Results of the Analysis of the National Register. <b>2023</b> , 22, 65-82	O
19	Emerging drugs for the treatment of moderately to severely active ulcerative colitis: review of phase II and III clinical trials. <b>2023</b> , 28, 27-42	O
18	What Is the Risk? Epidemiology and Evidence for Surveillance Regimens.	O
17	Constructing a prediction model of inflammatory bowel disease recurrence based on factors affecting the quality of life. 10,	0
16	Atherosclerotic Cardiovascular Disease in Inflammatory Bowel Disease: The Role of Chronic Inflammation and Platelet Aggregation. <b>2023</b> , 59, 554	O
15	Assessing acute colitis induced by dextran sulfate sodium in rats and its impact on gastrointestinal fluids. <b>2023</b> , 13, 1484-1499	О
14	Risks Factors Associated with the Development of Crohn Disease After Ileal Pouch-Anal Anastomosis for Ulcerative Colitis: A Systematic Review and Meta-Analysis.	O
13	Current perspectives on pediatric inflammatory bowel disease focusing on transitional care management. What should we consider?. <b>2023</b> , 46, 139-147	O
12	Risk factors for postoperative recurrence of ulcerative colitis-associated colorectal cancer´.	O
11	Biopsies from ulcer edge yield higher histological activity scores than biopsies from non-ulcerated mucosa in active ulcerative colitis. Publish Ahead of Print,	O
10	Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: a systematic analysis based on the Global Burden of Disease Study 2019. <b>2023</b> , 13, e065186	O
9	Vedolizumab for the Treatment of Chronic Pouchitis. <b>2023</b> , 388, 1191-1200	O
8	Mise ~jour sur le traitement mdicamenteux de la colite ulcfeuse. <b>2023</b> , 4, 19-26	O
7	Maladies inflammatoires chroniques intestinales : scores et optimisation des comptes rendus anatomopathologiques. <b>2023</b> ,	О
6	Intestinal Microbiota and miRNA in IBD: A Narrative Review about Discoveries and Perspectives for the Future. <b>2023</b> , 24, 7176	O

## CITATION REPORT

5 Identification of Critical Modules and Biomarkers of Ulcerative Colitis by Using WGCNA. Volume 16, 1611-16280

4	Interleukin-4 Gene Polymorphisms in Romanian Patients with Inflammatory Bowel Diseases: Association with Disease Risk and Clinical Features. <b>2023</b> , 13, 1465	O
3	Early transmural healing and its predictors assessed by magnetic resonance enterography in patients with Crohn⊠ disease receiving ustekinumab. <b>2023</b> , 16, 175628482311709	0
2	Very Early Pouchitis Is Associated with an Increased Likelihood of Chronic Inflammatory Conditions of the Pouch.	O
1	Rates of clinical remission and inadequate response to advanced therapies among patients with ulcerative colitis in Germany. <b>2023</b> , 38,	О